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Medulloblastomas represent the most frequent malignant brain tumour in children, and are 
thought to develop in the posterior fossa of the cerebellum. Some patients with 
medulloblastomas have a deficiency in the tumour suppressor gene Apc (Turcot’s syndrome). 
Although the majority of medulloblastomas arise sporadically, people with Apc mutations are 
92 times more likely to develop medulloblastomas. Apc encodes a very large protein known to 
function as a regulator of the Wnt signalling pathway. Activation of the canonical Wnt 
pathway leads to the stabilisation of β-catenin. In response to Wnt signals, β-catenin 
translocates to the nucleus where it interacts with the LEF/TCF family of transcription factors 
to activate transcription of target genes such as c-myc and cyclinD1. Mutations of Apc that 
cause an increase in β-catenin are found to be tumourgenic, whereas other mutations are not. 
Therefore it is thought that the main tumour suppression function of Apc is in its ability to 
destabilise and hence reduce cytoplasmic β-catenin. 
 
The central hypothesis of this thesis is that the loss of Apc can lead to the development of 
medulloblastoma. Work from other groups has reported activation of Wnt signalling in a 
proportion of primary medulloblastomas. We undertook a study to assess this by using the 
cre-loxP recombination system to mutate Apc in a temporal and spatial manner. This approach 
is necessary as Apc has many functions in development and Apc mutant mice (Apcmin) do not 
develop past embryonic day 6.5 (E6.5). To date, there are no known cre-strains available to 
mutate Apc specifically in the cerebellum at early postnatal stages, so we combined the cre-
loxP method with an avian retrovirus mediated method for tissue specific gene delivery 
(RCAS/tv-a system), in an attempt to create a strain of mice which carried the genotype Ntv-a 
+;ApcLoxP/LoxP. This would allow us to infect an RCAS-cre virus directly into the hindbrain at 
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postnatal day 4 (P4). However subsequent genotyping of these animals showed that none 
carried the desired genotype of Ntv-a +;ApcLoxP/LoxP, making it impossible for both copies of 
Apc to be mutated in a mouse most likely because both the Ntv-a and Apc transgenes were 
located on the same chromosome. Consistent with this, out of a total of 265 mice none were 
found to have the Ntv-a +;ApcLoxP/LoxP genotype.  
 
We then adopted an alternative method for mutating Apc by infecting ApcLoxP/LoxP mice directly 
with an AdCre virus. PCR analysis showed that Apc was mutated, however the AdCre virus 
did not infect cells of the cerebellum, and instead only infected the choroid plexus. In these 
animals, 7 of 94 (7%) developed hydrocephalus indicating that losing Apc in the choroid 
plexus may promote hydrocephalus.  
 
Finally, to address the role of Apc in normal hindbrain development, we crossed our 
ApcLoxP/LoxP mice to an En1cre strain which caused mutation in Apc from E8.5 in the mid-
hindbrain region. The resulting En1cre+;ApcLoxP/LoxP mutants displayed hydrocephalus in all 
ventricles and an in-growth of mesenchyme tissue at the mid-hindbrain border, closely 
associated with a tumour-like area of cells showing activated Wnt signalling. No mice were 
found to live past E18.5. 
 
In conclusion, the role of Apc in medulloblastoma remains unclear. Future studies could use a 
different technique to mutate Apc such as crossing ApcLoxP/LoxP mice to the new nestin-creER 





Central nervous system (CNS) malignancies are the most common solid tumours in 
childhood, and are the leading cause of cancer related death in this age group 
(Robertson 2006). There are five types of embryonic tumours that have been 
described in the CNS: medulloepithelioma, ependymoblastoma, medulloblastoma 
(MB), atypical teratoid/rhabdoid tumour (ATRT) and supratentorial primitive 
neuroectodermal tumour (PNET) (Ellison 2002).  MBs are the most common type of 
malignant brain tumour that occur during childhood (Gilbertson 2004), and are 
classified as a malignant tumour of the cerebellum that preferentially occurs in 
children, and has the tendency to metastasise  (Kleihues et al. 2002). Peak incidence 
of MB is in the eighth year, but while most cases present within the first 20 years, a 
significant proportion (30%) occurs in adulthood (Cervoni et al. 1994).  MBs were 
originally identified by Bailey and Cushing (1925) when they were creating the first 
comprehensive classification of CNS tumours. They recognised similarities between 
its cytological features and those of the embryonic medullary velum  (Bailey 1925; 
Rorke 1994). Other CNS tumours composed of blast-like cells with a high nuclear : 
cytoplasm ratio, with little cytological differentiation and a high mitotic count have 
since been classified as embryonal tumours with the MB (Ellison 2002). 
 
Five different variants of MB have been described: Melanotic MB and 
medullomyoblastoma are very rare, accounting for around 1% of MBs (Dolman 
1988). Melanotic MB are distinguished from other variants by the presence of 
melanin in cells, clusters of which may occasionally have an epithelioid appearance 
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and a tubular or papillary architecture (Dolman 1988). Medullomyoblastomas show 
degrees of rhabdomyoblastic differentiation (Smith & Davidson 1984). Because of 
their rarity, the biological behaviours of the melanotic MB and medullomyoblastoma 
have not been established as significantly different from that of the classic MB 
(Ellison 2002).  Large cell MB is an aggressive variant of MB with a poor prognosis. 
These are also rare, making up only 4% of MBs (Brown et al. 2000), and are 
described as containing large tumour cells with prominent nucleoli and abundant 
cytoplasm, and also characterised by anaplasia (Gilbertson 2004). The desmoplastic 
variant of MB accounts for around 15% of MBs (Giordana et al. 1997). They contain 
nodules of tumour cells that commonly show neurocytic differentiation and are 
surrounded by collagen rich tissue (Gilbertson 2004). And lastly, the classic variant of 
MB (accounting for around 80% of MBs), tend to grow as sheets of cells with a high 
nuclear : cytoplasm ratio with the capacity to invade adjacent brain tissue. They lack 
the nodular / desmoplastic architectural features of desmoplastic MBs, but can display 
Homer-Wright rosettes or palisades (Ellison 2002). All of these variants are graded as 
grade IV by the World Health Organisation (WHO). 
 
Classic symptoms of MB occur as a result of increased intracranial pressure, 
including headache, vomiting, irritability or lethargy, and sometimes with symptoms 
due to involvement of local structures, such as ataxia, head tilt or cranial nerve palsies 
(Robertson 2006). 
 
1.1.1 Medulloblastoma treatment 
MBs represent a significant challenge in the field of neuro-oncology due to their 
highly aggressive nature and sequelae from the tumour and treatment. There are 3 
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main prognostic markers for a patient with MB: patient’s age at diagnosis, the extent 
of postoperative residual disease, histological subtype of MB, and tumour metastasis.   
 
MB in infants (children under 3 years of age), is twice as likely to progress within 5 
years of diagnosis than MB occurring in older children (Zeltzer et al. 1999). Before 
the1980’s, the treatment of infants was the same as that of older children, but their 
survival and subsequent standard of life was significantly worse. One of the main 
reasons for this is due to the use of radiation treatment. Radiation is a highly effective 
treatment for MB, however it can also cause severe damage to the developing brain. 
Therefore, treatment of MB in infants is generally restricted to surgery and 
chemotherapy alone (Gilbertson 2004). Another reason why young patients seem to 
have a higher mortality rate than those over 3 years at age of diagnosis, is due to 
inherent differences in disease biology. ATRTs are highly aggressive tumours that are 
distinct from MBs, but share similar characteristics clinical signs and symptoms and 
radiological features (Rorke et al. 1996). They are more common in infants, and cause 
a much higher mortality rate than MB. ATRTs were in previous years not 
differentiated from MBs, so an infant with an ATRT would have been included in MB 
clinical trials (Gilbertson 2004). This would contribute to the very high mortality seen 
in very young children.  
 
MBs have a tendency to metastasise, with around a third of patients showing signs of 
metastasis within the CNS at diagnosis (Zeltzer et al. 1999), and a small proportion of 
MBs have also been seen to metastasise to extraneural areas such as the bone, bone 
marrow, lungs, liver, and lymph nodes (Eberhart et al. 2003). MB is staged according 
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to Chang’s criteria (Chang 1969) for classifying tumour and metastasis stage in MB, 
and metastases remain one of the most important prognostic markers of MB.  
 
Lastly, a large volume of postoperative residual tumour (≥1.5cm2 on a postoperative 




Surgery is the initial treatment for most children with brain tumours. With surgical 
resection, it is essential to extract as much of the tumour as possible as this will 
increase the patients chance of survival. However, the extent of resection must be a 
balance between the benefit of taking as much tumour material as possible, and the 
risk of damaging adjacent neuroanatomical structures. 
 
1.1.1.2 Radiation Therapy 
Radiation therapy is usually the first adjuvant treatment after surgery for MB. It was 
initially developed in the early 1900’s for the treatment of adult gliomas and pituitary 
tumours (Robertson 2006). Radiation therapy is normally applied to the primary 
tumour site, or in the case of a tumour with a tendency to metastasise (ie. MB), it is 
applied to the entire craniospinal axis.  
 
1.1.1.3 Chemotherapy 
Chemotherapy is defined as the treatment of disease with chemical substances, and in 
particular, the treatment of cancer with cytotoxic and other drugs. Broadly, most 
chemotherapeutic drugs work by impairing mitosis, effectively targeting fast-dividing 
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cells. As these drugs cause damage to cells they are termed cytotoxic. Unfortunately, 
chemotheraputic drugs cannot differentiate between cancer cells and normal cells. 
The normal cells will grow back once the treatment stops, however during the 
treatment regimen, side effects occur.  The normal cells most commonly affected by 
chemotherapy are rapidly dividing cells such as blood cells, epithelial cells in the 
mouth, stomach and bowel, and the hair follicles; resulting in low blood counts, 
mouth sores, nausea, diarrhoea, and/or hair loss.  Different drugs may affect different 
parts of the body.  
 
Chemotherapy was initiated for the treatment of paediatric brain tumours such as MB 
in the 1970’s. Studies carried out by the Childrens Cancer Group (CCG) and the 
International Society for Paediatric Oncology (SIOP) have demonstrated the 
efficiency of post-irradiation chemotherapy in children with high-stage disease, 
although, trials have failed to show the same efficiency in low-stage disease (Evans et 
al. 1990; Tait et al. 1990).  
 
New chemotherapeutic strategies are being developed that specifically focus on 
targeting tumour cells to reduce side effects of conventional chemotherapeutic drugs. 
Identification of molecular differences between brain tumour cells and normal healthy 
cells has opened the way for a number of therapeutic strategies that take advantage of 
these differences. Targeted therapies take advantage of these differences to inhibit 
growth of tumour cells, for example, by inhibiting growth of blood cells (anti-
angiogenic therapy), inhibiting signal transduction pathways, using immunotherapy, 
and regulating gene expression (Robertson 2006). 
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1.1.1.3.1 Anti-angiogenic Therapy 
Tumour growth depends on the recruitment of blood vessels, a process called 
angiogenesis. Angiogenesis occurs during development, however, it also important 
later in tissue regeneration (Kerbel & Folkman 2002). Cancer cells create an 
“angiogenic switch” to promote angiogenesis in early tumour development. This 
involves turning on genes involved in the growth of new blood cells such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-
8 (IL-8), placenta-like growth factor (PLGF), transforming growth factor-β (TGF-β) 
and others (Fukumura et al. 1998; Relf et al. 1997). Fibroblasts in or near the tumour 
bed begin to produce these pro-angiogenic factors and tumours also recruit progenitor 
endothelial cells from bone marrow (Fukumura et al. 1998; Shi et al. 1998). The 
angiogenic switch also involves the down-regulation of angiogenic suppressor 
proteins such as thrombospondin (Dameron et al. 1994). 
 
Anti-angiogenic drugs can either act directly on the tumour cells to inhibit synthesis 
of proteins such as bFGF, VEGF and TGF-α or other receptors on the endothelium 
that are expressed by the tumour cells. An example of such a drug is ZD1839 (Iressa) 
(Kerbel & Folkman 2002). Direct angiogenesis inhibitors, such as endostatin, target 
the microvascular endothelial cells that are recruited to the tumour bed and prevent 
them from responding to various endothelial mitogens (Kerbel & Folkman 2002). 
 
1.1.2 What factors lead to Medulloblastoma development? 
Understanding the biology of MBs will be a key factor in future treatment strategies. 
It is unlikely that current methods of combating MBs can significantly increase 
survival rate among patients, and also decrease the serious long-term side effects that 
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affect survivors’ lives. The aberrant activation of several cell-signalling pathways 
have been implicated in MB formation, and investigation of these pathways should 
lead to the development of new treatments and risk-stratification tools for MB in the 
near future. Two of these pathways, the hedgehog and Wnt pathways, where aberrant 
signal transduction in MBs are thought to occur are discussed below. 
 
1.1.2.1 Sonic Hedgehog (Shh) 
The Drosophila melanogaster gene hedgehog (hh) and its mammalian homologues 
Shh, Desert hedgehog (Dhh), and Indian hedgehog (Ihh) are secreted glycoproteins 
that have key roles in tissue patterning acting as morphogens involved in patterning 
many systems, including the limb and midline structures in the brain and spinal cord. 
The loss or reduction of Hh signalling is associated with numerous developmental 
deficits or malformations, one of the most striking of which is the cyclopia associated 
with loss of Shh signalling (Muenke 2001). The Shh pathway acts through patched 
1(Ptc1), a 12-pass transmembrane receptor that represses the activity of the protein 
smoothened. Smoothened is a 7-pass transmembrane associated protein which is 
closely related to the frizzled family of Wnt receptors (discussed below). Ptc1 is 
thought to suppress smoothened indirectly, resulting in GLI (glioma-associated 
oncogene homologue) transcription factors to be bound to microtubules in the 
cytoplasm. This is done by a complex which includes fused and suppressor-of-fused. 
GLI 1 is sequestered into this complex, preventing it from activating gene 
transcription, while GLI 2 and GLI 3 are cleaved to produce truncated transcriptional 
repressors. The binding of Shh to Ptc1 inhibits Ptc1’s suppression of smoothened, 
which in turn disrupts the complex containing fused and suppressor-of-fused. 
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Subsequently, GLI 1 is released and activates gene transcription, whereas GLI 2 and 
GLI 3 cleavage is blocked (McMahon et al. 2003) (Figure 1.1). 
 
The involvement of the Hh pathway in human cancer was first appreciated upon the 
identification of Ptch as the tumour suppressor in Gorlin’s syndrome (also known as 
basal cell nevus syndrome (BCNS)). Sufferers of Gorlin’s syndrome can display a 
variety of abnormalities such as craniofacial and rib alterations, polydactyly, 
syndactyly, and spina bifida as well as a multitude of tumour types such as fibromas 
of the ovaries and heart, cysts of the skin, meningiomas, basal cell carcinomas (BCCs) 
and medulloblastomas (Johnson et al. 1996). A study by Johnson et al (1996) found 
altered Ptch sequences in germline DNA from BCNS individuals and also in BCCs. 
Supporting this, is a study by Hahn et al., (1996) found smoothened (SMOH) 
mutations in 20% of sporadic BCCs. Shh signalling was first linked to MB through 
studies of the human PATCHED1 (PTCH1) gene. 10-20% of sporadic MBs have been 
found to carry mutations at the PTCH1 locus (Pietsch & Wiestler 1997; Raffel 1997b; 
Xie et al. 1997), which suggests that defects in Shh/Ptc signalling can contribute to 
the development of MBs. PTCH1 mutations are not the only mutations of the Shh 
pathways found in MBs. Activating mutations of SMOH have been detected in up to 
5% of sporadic MBs (Reifenberger et al. 1998), and a study by Taylor et al. (2002) 





The first unconditional proof showing that mutations in the Hh pathway can lead to 
MB development came from the study of Ptc1+/- mice (Goodrich et al. 1997; Hahn et 
al. 1998) which have had one copy of Ptc deleted. Homozygous Ptc1-/- mice die at 
E9.5 with severe defects in the cardiovascular and nervous systems, but heterozygotes 
are viable and initially the only phenotypes are increased body size and a low 
incidence of polydactyly (Goodrich et al. 1997). However, at around 5 months of age, 
between 15% and 25% of mice develop aggressive cerebellar tumours with the 
characteristic small, round cells on the surface of the cerebellum that MB possess 
(Goodrich et al. 1997; Wetmore et al. 2000). Studies trying to determine whether the 
second allele of Ptc1 must be lost to induce tumourigenesis have been contradictory 
with studies by Wetmore et al. (2000), Zurawel et al. (2000) and Romer et al. (2004) 
all detecting wild type Ptc1 RNA in tumours from Ptc1+/- mice (Raffel 1997a; Romer 
et al. 2004; Wetmore et al. 2000). However, contradicting this is a report from 
Berman et al. (2002) who found that wild type Ptc1 may be silenced possibly through 
DNA methylation (Berman et al. 2002). Although this study was conducted using 
autografted cell lines, and the Hh pathway has been shown to undergo silencing when 
primary cell lines are cultured in vitro (Romer et al. 2004).  
 
The mechanism by which dysregulation of Hh signaling leads to MB formation is still 
unclear, however there is evidence to suggest a close connection between activated 
Hh signaling and impaired cell-cycle control. Studies by Pomeroy et al. (2002) and 
Lee et al. (2003) which looked at the gene expression in MBs using microarrays, 
found elevated levels of Gli1, N-Myc, C-Myc, CyclinD1 and CyclinD2. These genes 
were also found to be expressed in the developing cerebellum (Lee et al. 2003; 
Pomeroy et al. 2002) which implies that MB cells may be similar to granule cell 
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precursors (GCPs). Shh has been linked to cell-cycle control from a study by Kennedy 
and Rowitch (2000) which showed that Shh could induce expression of the G1 cyclin 
genes (Kenney & Rowitch 2000). Shh stimulation has also been shown to hamper exit 
from the cell-cycle, in part through blocking cell-cycle arrest induced by the cyclin-
dependent kinase inhibitor p21CIP1 (Fan & Khavari 1999). 
 
1.1.3.2 Wnt Signalling 
Along with the hedgehog proteins and other families of secreted factors, Wnt proteins 
have been implicated in a wide range of biological processes. Wnt1, the first Wnt 
protein, was discovered in 1982 in a study by Nusse and Varmus. This study looked at 
whether the mouse mammary tumour virus (MMTV), an oncogenic retrovirus, 
integrated into a certain region of the host genome. The study showed that the MMTV 
integrated into the Wnt1 locus, and Wnt1 was subsequently cloned (Nusse & Varmus 
1982). From this landmark discovery, the role of Wnt genes in cancer was the main 
area of research in the 1980’s in this field (reviewed by Nusse and Varmus 1992). The 
focus of Wnt research changed when the Drosophila orthologue of Wnt1 (wg) was 
discovered (Cabrera et al. 1987; Rijsewijk et al. 1987), and with the phenotypic 
analysis of Wnt1 mutations in mice (McMahon & Bradley 1990; Thomas & Capecchi 
1990), Wnt research largely changed focus to now study their effects in development. 
The discovery that wg was a Wnt family member allowed the powerful genetics of 
Drosophila to be applied to understanding Wnt gene function. More recently, with the 
discovery that Apc is the tumour suppressor involved in familial adenomatous 
polyposis, Wnt research has come full circle and many researchers are looking at 




To date, in vertebrates, 16 Wnt genes have been identified in Xenopus, 11 in chick, 
and 12 in zebrafish. Humans have 19 Wnt genes and there are also 19 in the mouse. 
These are highly conserved between species, especially between vertebrates, and only 
slightly less conserved between vertebrates and invertebrates. A comprehensive list of 
Wnt genes can be found at the Wnt homepage at 
http://www.stanford.edu/~rnusse/wntwindow.html, maintained by Roel Nusse.  
Wnt signals are transduced through at least three distinct intracellular signalling 
pathways including the canonical ‘Wnt/β-catenin’ pathway, the ‘Wnt/polarity’ 
pathway and the ‘Wnt/Ca2+’ pathway (Adler & Lee 2001; Kuhl et al. 2001; Miller et 
al. 1999). Each of these pathways can be activated by distinct sets of Wnt and 
Frizzled receptor pairs which achieve alternative cellular responses.  
 
The main known function of the Wnt/polarity (also known as the Wnt/JNK pathway) 
is for specifying cell polarities in epithelial cells (Adler 2002). This 
pathway involves the cadherin-related transmembrane molecule flamingo (Fmi), the 
proteoglycan knypek (Kny), and the PDZ molecule strabismus (Stbm) and branches at 
the level of Dsh from the canonical pathway. Frizzled, which with the help of protein 
kinase C (PKC), activates c-Jun N-terminal kinase (JNK) (Kinoshita et al. 2003). In 
vertebrates, this pathway controls cell movements during gastrulation (Tada & Smith 
2000; Wallingford & Harland 2001). In Drosophila, this pathway has many 
developmental roles such as regulating asymmetric cell divisions in neuroblast 
populations, and ensuring the appropriate orientation of the hairs on the adult wing 




Little is known about biological function of the Wnt/Ca2+ pathway. The Wnt Ca2+ 
pathway leads to the release of intracellular calcium, possibly via G-proteins. 
Phospholipase C (PLC) and PKC are activated causing increased Ca2+ which leads to 
dephosphorylation of the transcription factor NF-AT. NF-AT accumulates in the 
nucleus and, in xenopus embryos, NF-AT suppresses canonical Wnt signals during 
axis formation (Huelsken & Behrens 2002).  
 
1.1.3.2.1 The canonical Wnt signalling pathway 
The β-catenin-dependent, or canonical, Wnt signalling pathway was the first to be 
discovered and is best understood Wnt pathway. During the remainder of this thesis, 
any reference to the ‘Wnt pathway’ will be referring to the canonical pathway. This 
pathway acts through β-catenin to activate specific target genes, which in turn, are 
able to modulate cell fate, apoptosis and proliferation (Cadigan & Nusse 1997; Miller 
et al. 1999; Wodarz & Nusse 1998). 
 
The canonical Wnt signalling pathway is activated by a Wnt protein binding to its 
receptor, Frizzled. Frizzled has seven-transmembrane spanning receptors, which may 
be coupled to heterotrimeric G proteins. Various secreted factors, such as cerberus 
(Cer) and FrzB, can bind to Wnts and block the interaction with frizzled proteins. 
Dickkopf (Dkk) antagonises Wnt action by blocking access to the LRP co-receptor. 
 
The binding of Wnt to Frizzled recruits Dishevelled (Dsh) to the membrane and 
negatively regulates GSK-3β, causing the complex between Apc, Axin and GSK-3β 
to lose its ability to bind and cause the phosphorylation β-catenin via a ubiquitin-
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ligase complex. This leads to a build-up of stabilised intracellular β-catenin in the 
cytoplasm (Fearnhead et al. 2001). β-catenin then translocates to the nucleus where it 
acts as a transcriptional co-activator by associating with members of the T cell factor 
(TCF) and lymphoid enhancer factor (LEF) family of transcriptional activators  
(Roose & Clevers 1999). This β-catenin – transcription factor complex regulates 
transcription of target genes such as c-myc and cyclin D1, which are regulators of cell 
growth and proliferation  (Nathke 1999) (Figure 1.2). 
 
In the absence of a Wnt signal, β-catenin is sequestered in the cytoplasm and 
destabilised by a complex containing Axin, GSK3β, and Apc which phosphorylates 
β-catenin by GSK3β (Behrens et al. 1998; Hart et al. 1998). Phosphorylated β-catenin 
becomes ubiquitylated and is targeted for degradation by the proteasome via a 
ubiquitin ligase complex (Zeng et al. 1997). Hence β-catenin cannot translocate to the 
nucleus and turn on transcription of target genes. Both Apc and Axin are key negative 
regulators of the Wnt signalling pathway. Axin binds to Apc forming a complex 
which in turn binds both GSK3β and β-catenin. This is important not only as GSK3β 
requires both Apc and Axin to bind β-catenin, but also because both Apc and Axin are 
phosphorylated by GSK3β, which strengthens the binding of β-catenin (Ikeda et al. 
1998). Axin was once thought to be merely a scaffold protein linking other members 
of the complex, however, it is now thought to play a more dynamic role in the 
degredation of β-catenin by binding to the tail of LRP in response to a Wnt signal 
(Mao et al. 2001). Membrane tethering of Axin to LRP is thought to be enough to 
activate signalling (Brennan et al. 2004) possibly by titration of Axin away from the 
Apc/Axin/GSK3β complex.  GSK3β phosphorylates three conserved residues in the 
amino-terminal region of β-catenin, Ser 33, Ser 37, and Thr 41. However, studies 
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have shown that for efficient phosphorylation casein kinase 1 (CK1) should 
phosphorylate β-catenin at Ser 45. This then serves as a priming site for GSK3β 
phosphorylation (Amit et al. 2002; Liu et al. 2002; Yanagawa et al. 2002). This 
explains why many human tumours carry mutations of Thr 41 and Ser 45 of β-catenin  
(Polakis 2000). 
 
β-catenin has another main function outside the Wnt pathway.  β-catenin has been 
shown to interact with other proteins such as E-cadherin and α-catenin (Hulsken et al. 
1994), and play a critical role in cellular adhesion. The cytoplasmic domains of E-
cadherin, a calcium ion dependent cell adhesion molecule, bind either β-catenin or γ-
catenin (plakoglobin) (Aberle et al. 1996). These catenin proteins then complex with 
α-catenin which acts as a bridge to bind actin molecules making up the cytoskeleton 
(Aberle et al. 1996). 
 
The deregulation of Wnt signalling has emerged to be an important step in human 
oncogenesis (Polakis 2000). Mutations of proteins in the Wnt pathway occur in 
around 15% of sporadic MBs (Baeza et al. 2003; Eberhart et al. 2000; Huang et al. 
2000; Koch et al. 2001), and can cause heritable forms of the disease when 
transmitted through the germline (Robertson et al. 2004). In the majority of cases, 
mutations that cause aberrant Wnt signalling block the breakdown of β-catenin in the 
cytoplasm of the cell, allowing it to translocate to the nucleus and turn on 
transcription of Wnt target genes such as c-myc and cyclin D1.  The Wnt/β-catenin 
pathway will be discussed in more detail in a later section.  
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Most of the mutations of the Wnt pathway that have been reported in sporadic MBs 
have targeted residues S33 and S37 of β-catenin and account for between 5-10% of 
cases, however, less common mutations have been described in the Apc tumour 
suppressor gene at a frequency of around 4% (Huang et al. 2000).  
 
1.1.4 Familial Adenomatous Polyposis (FAP) 
The Apc gene encodes a large, multi-domain protein that was initially identified by 
positional cloning of the Familial Adenomatous Polyposis (FAP) locus (Groden et al. 
1991; Kinzler et al. 1991) following mutational analyses of unrelated families with 
FAP.  FAP is a dominantly inherited colorectal cancer syndrome which is 
characterised by multiple (potentially thousands) of colorectal adenomas throughout 
the colorectum and duodenum (Galiatsatos & Foulkes 2006).If left untreated, this will 
progress to colorectal cancer within the third to fourth decade of life (Bisgaard et al. 
1994). To date, there have been over 700 disease causing Apc mutations identified 
(Galiatsatos & Foulkes 2006)leading to the introduction of a premature stop codon 
leading to truncation of the protein product in the C-terminal region. Of these, 68% 
are frameshift mutations, 30% are nonsense mutations, and 2% are large deletions 
(Beroud & Soussi 1996). There is also an association between tumours of the CNS 
and multiple colorectal polyps in some FAP patients, a condition known as Turcot’s 
syndrome. Patients suffering from this condition have mutations in Apc. Although 
brain tumours arise sporadically in the general population, patients with a germline 




1.2 Adenomatous Polyposis Coli (Apc) 
 
Apc encodes a large multidomain protein that plays an integral role in Wnt signalling 
and cell adhesion (Fearnhead et al. 2001), as well as being implicated in apoptosis 
(Morin et al. 1996) and neuronal cell migration (Munemitsu et al. 1994). The Apc 
gene is located at human chromosome 5q21 spanning 8535bp, with 21 exons 
(Thliveris et al. 1996), and encoding a predicted 2843 amino acid polypeptide in its 
commonest isoform (Santoro & Groden 1997). Exon 10A is the subject of alternative 
splicing and adds an additional 18 amino acids to the Apc protein when it is spliced in 
(Xia et al. 1995). Exon 15 comprises over 75% of the coding sequence and is the most 
common target for both germline and somatic mutations (Beroud & Soussi 1996). 
Originally Apc was thought to comprise of 15 exons (Groden et al. 1991), however, 
studies such as the one by Bardos et al (1997), showed by using RT-PCR that 
alternative mRNA isoforms exist that encode unique Apc proteins. This study 
indicates that the Apc gene codes for a complex pattern of gene products that are 
generated on the basis of alternative splicing (Bardos et al. 1997).   
  
The Apc protein contains an armadillo region in the N-terminus, an oligomerisation 
domain, a number of 15-and 20- amino acid repeats in its central portion, and a C-
terminus that contains a basic domain and binding sites for EB1 and the human discs 
large (HDLG) protein. These multiple domains of the Apc protein allow it to interact 
with numerous protein partners (Fearnhead et al. 2001) (Figure 1.3). 
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The armadillo region consists of seven repeats which bear a high degree of homology 
to β-catenin and its Drosophila homologue, armadillo (Kinzler et al. 1991). The 
armadillo region has been shown to bind the regulatory subunit B56 of protein 
phosphatase 2A (PP2A) (Seeling et al. 1999),which is an enzyme which can also bind 
axin. Indeed, the findings from a study by Hsu et al. (1999) indicated that PP2A might 
interact with the Apc/Axin/GSK3β/β-catenin complex and antagonise the GSK3β 
phosphorylation of β-catenin (Hsu et al. 1999).  
 
The oligomerisation domain in the Apc protein, located in the N-terminus, allows Apc 
to form homo-dimers (Su et al. 1993). This domain makes it possible for Apc to form 
dimers with both wild-type and truncated mutant forms of Apc.  
 
There are three 15 and seven 20 amino acid repeats located in the central portion of 
the Apc protein. These are areas which bind β-catenin (Fearnhead et al. 2001), 
however, β-catenin binding at these sites can only occur after phosphorylation of each 
site by GSK3β (Munemitsu et al. 1995; Rubinfeld et al. 1996).  Downregulation of β-
catenin is dependent on the presence of at least three of the seven 20 amino acid 
repeats in Apc (Rubinfeld et al. 1997). The majority of truncated mutant proteins lack 
all or most of the 20 amino acid repeats, suggesting that these are targets for 
elimination during tumourigenesis (Polakis 1997). 
 
The basic domain is situated between amino acids 2200 and 2400 in the C-terminus 
(Groden et al. 1991). It derives its name from the high proportion of (basic) arginine 
and lysine residues, however this domain also contains a very large number of proline 
residues. Studies by Smith et al. (1994) and Munemitsu et al. (1994) have shown that 
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Apc binds microtubules at the C-terminal (Munemitsu et al. 1994; Smith et al. 1994a). 
Taking this further, in the study by Munemitsu et al. (1994), they show that mutant 
Apc fragments only associate with cytoplasmic microtubules if they contain the C-
terminal portion. Moreover, a recent study by Moseley et al. (2007) showed that actin 
not only binds to the basic region of Apc, but also competes with microtubules for 
binding to this domain. Tumour formation and metastasis involve coordinated 
changes in the actin and microtubule cytoskeletons (Moseley et al. 2007), so it is of 
note that truncated Apc proteins found in colorectal tumours rarely retain the basic 
domain (Fearnhead et al. 2001). The ability of Apc to assemble and/or associate with 
microtubules may in part explain the localisation of Apc to the leading edge of 
migrating cells, a region where microtubule assembly is required, and in addition may 
lend itself to the observations of disordered cell migration in models of Apc 
overexpression and in animal models of FAP (Mahmoud et al. 1997; Mahmoud et al. 
1999; Nathke et al. 1996; Wong et al. 1996). 
 
The C-terminus region contains the binding site for end binding protein 1 (EB1) and 
Human Disks Large (hdlg). EB1 is a microtubule plus-end tracking protein that binds 
to and partially co-localizes with Apc in vivo (Kita et al. 2006). The presence of EB1 
at the plus ends of microtubules occurs independently of Apc (Berrueta et al. 1998; 
Morrison et al. 1998). In fact, if the EB1 binding domain is deleted from Apc, then 
Apc is still able to bind microtubules (via its basic domain), however, the study by 
Askham et al. (2000) suggest that the interaction between Apc and EB1 targets Apc to 
microtubule tips, and without this interaction, Apc binds microtubules randomly 
(Askham et al. 2000).  
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The final 72 amino acids of Apc are necessary for hdlg binding (Matsumine et al. 
1996). The hdlg protein is the human homologue of the Drosophila Discs Large (dlg) 
tumour suppressor protein which when lost in Drosophila results in neoplastic growth 
in the imaginal disc of the developing embryo (Bryant et al. 1993). Overexpression of 
Apc can halt progression of the cell cycle from G0/G1 to S phase (Baeg et al. 1995), 
with a study by Ishidate et al. (2000) showing that an Apc-hdlg complex is crucial for 
this cell cycle blocking ability of Apc (Ishidate et al. 2000). 
 
 
1.2.1 Functions of Apc 
Possibly the best understood function of Apc is in its role as a negative regulator in 
the Wnt signalling pathway. As discussed earlier, Apc forms a complex with GSK3β 
and Axin to bind β-catenin which leads to its breakdown in the cytoplasm. Truncation 
mutations of Apc that render it unable to form this complex with GSK3β and axin, 
leads to an accumulation of β-catenin which causes changes in the transcriptional 
activation of Wnt target genes such as c-myc, cyclin D1, ephrins and capsases (Chen 
et al. 2003; Fodde 2002; van de Wetering et al. 2002). These genes are known to have 
the ability to change the proliferation and differentiation state of cells (Nathke 2004). 
Therefore, Apc is thought of a negative regulator of the Wnt signalling pathway by 
binding to and, hence, down-regulating free cytoplasmic β-catenin. This was shown 
experimentally by Munemutsu et al. (1995) who demonstrated a dramatic reduction in 
intracellular β-catenin by transiently transfecting SW480 colorectal cancer cells with 
wild type Apc protein. These colorectal cancer cells have a mutated Apc protein and 
are unable to mark β-catenin for degradation, and hence have very high β-catenin 
levels (Munemitsu et al. 1995). Therefore, by adding wild type Apc protein, they were 
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able to re-establish a functional Wnt pathway. In summary, losing Apc function in the 
canonical Wnt signalling pathway has the same result as constantly stimulating the 
pathway. 
 
The other main function of Apc lies in its ability to interact with the cytoskeleton. Apc 
is highly expressed in the peripheral ends of some microtubules in migrating epithelial 
cells (Nathke et al. 1996). In polarised cells, the majority of Apc expression can be 
seen at the basal surface where the plus ends of microtubules terminate (Mogensen et 
al. 2002). Apc has also been linked to some aspects of formation and/or maintenance 
of mitotic spindles. Apc can associate with the cytoskeleton in at least two ways. It 
can either directly bind to microtubules (Munemitsu et al. 1994; Smith et al. 1994b), 
or indirectly connect with the actin cytoskeleton  (Townsley & Bienz 2000). As stated 
previously, Apc can bind microtubules directly at the C-terminal via the basic domain 
and the EB1 domain. However, as shown by Zumbrunn et al. (2001), Apc can still 
associate with microtubules even in mutated forms of Apc lacking the basic domain 
(Zumbrunn et al. 2001).   
 
Apc is found in the nucleus as well as the cytoplasm, and contains several nuclear 
import and export signals (Henderson & Fagotto 2002). It is possible that Apc may 
play a role in the shuttling of β-catenin in the nucleus, however, the shuttling of β-
catenin from the cytoplasm to the nucleus can take place in the absence of Apc 
(Henderson & Fagotto 2002). That leaves the possibility that Apc may play a role in 
shuttling β-catenin out of the nucleus and into the cytoplasm for subsequent 
degradation. Along the length of the Apc protein are nuclear export sequences (NES). 
Indeed, a paper by Henderson (2000) showed that mutating NESs on Apc causes a 
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build up of β-catenin in the nucleus, and conversely, overexpression of wild-type Apc 
in Apc deficient colon cancer cells has been shown to increase nuclear export and 
degradation of β-catenin (Henderson 2000).These findings suggest that wild-type Apc 
controls the nuclear accumulation of β-catenin by a combination of nuclear export as 
well as cytoplasmic degradation.  
 
1.2.2 The role of Apc in cancer 
As discussed earlier, abberant Wnt signalling is thought to be involved in 
medulloblastoma. However, dysregulation of the Wnt pathway is thought to play a 
role in other types of cancers. Indeed, 20% of gastric carcinomas screened have 
activating mutations in β-catenin (Clements et al. 2002). In melanomas, when pulling 
the results of various screening studies, it appears that 5% of all melanomas have 
either a mutation of Apc or β-catenin (Giles et al. 2003). Hepatoblastomas represent 
the most frequent liver cancer in children, and although most cases are sporadic, there 
is a greatly elevated incidence in patients with FAP (Giles et al. 2003). When 
hepatoblastomas were screened for mutations in either Apc or β-catenin, 51% were 
found to carry a mutation in exon 3 on β-catenin, which affected the ability of GSK3β 
to bind and phosphorylate β-catenin (Blaker et al. 1999; Jeng et al. 2000; Koch et al. 
1999; Park et al. 2001; Taniguchi et al. 2002; Wei et al. 2000). Therefore, since 
dysregulation of the Wnt pathway can lead to various types of cancers, and that Apc 
plays a key role in the Wnt pathway, it is easy to see how mutations of Apc can lead 
to cancer development.  
 
However, this model is complicated when you consider that there are pathways 
outside the Wnt signalling pathway which have the ability to regulate levels of β-
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catenin. These include the p53-inducible Siah-1 protein (Liu et al. 2001), and retinoid 
X receptor (Xiao et al. 2003). This makes it difficult to establish how mutations in 
Apc can lead to colon cancer through the de-regulation of β-catenin. This lends 
weight to the idea that Apc’s other functions such as its role in the cytoskeleton also 
play a role in its role in cancer. Indeed, in early mitosis, Apc localises to the end of 
microtubules that are embedded in kinetochores, but Apc is also present in spindle 
microtubules and centrosomes (Dikovskaya et al. 2004; Louie et al. 2004). Indeed, 
mutations in APC have been in the development of chromosomal instibility early in 
tumour formation (Shih et al. 2001). To investigate further Apc’s role in 
microtubules, Dikovskaya et al. (2004) conducted a study using Xenopus egg extracts 
which were arrested in metaphase of meiosis II (referred to as cytostatic factor 
extracts). Their results showed that a lack of Apc leads to defects in the structure of 
mitotic spindles including a general loss of mictrotubule mass and redistribution of 
microtubule density from the centre of spindles towards the poles. The resulting 
phenotype could only be rescued by Apc protein containing intact microtubule 
binding site (Dikovskaya et al. 2004). Other effects such as changes in asters formed 
in the absence of chromatin indicate that changes in cytostatic factor extracts’ spindle 
structure that result from Apc depletion can be at least partially attributed to direct 
effects on microtubule network removal (Dikovshaya et al. 2004). The study then 
went on to show that loss of Apc leads to chromosome mis-segregation suggesting 
that mutations in Apc could lead to cancer by causing aneuploidy (Dikovskaya et al. 
2004). This reinforces other studies by Fodde et al. (2001), and Green and Kaplan 
(2003) who reported aberrant spindle structures in cells expressing mutant Apc. 
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There is a strong relationship between the functions of Apc and colorectal cancer. In 
the gut, all cells except stem cells have a very short lifespan. Epithelial cells 
differentiate and migrate out from the base of the crypts of Lieberkühn and are usually 
exfoliated within 3-5 days. A very strict balance must be maintained between 
differentiation, proliferation, cell adhesion and migration to ensure healthy gut 
maintenance. Mutations in Apc can affect the process of cell migration through its 
interactions with microtubules and the actin cytoskeleton causing cells to move less 
efficiently leading them to spend more time in the toxic environment of the gut which 
could in turn lead to further mutations. Also, defective mitotic spindles can cause 
genetic instability (Fodde et al. 2001) which would have major consequences as 
possibly lead to tumour formation if the mutation happened in a gut stem cell. Further, 
mutations of Apc would lead to abnormal β-catenin regulation which could lead to 
abnormal cell differentiation. All these factors may explain why a mutation in a single 
gene can have such severe consequences and lead to malignancies.  
 
A study by Sansom et al. (2004) looked at the role Apc plays in the small intestine 
conditionally mutated Apc in this area which lead to altered crypt-villus architecture 
and morbidity after five days (Sansom et al. 2004). The study showed that the loss of 
Apc activated nuclear β-catenin which was seen by immunohistochemistry. They 
observed that differentiation, migration, proliferation and apoptosis were perturbed 
such that Apc-deficient cells maintain a crypt progenitor-like phenotype. To follow up 
this study, the same group created a double mutant for Apc and Myc (Sansom et al. 
2007). In this double mutant, the changes conferred by Apc deficiency are rescued by 
Myc deficiency even in the presence of elevated nuclear β-catenin. A previous study 
showed that Myc deficient stem cells are selected against with the wild-type 
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surrounding cells outcompeting the mutant cells (Muncan et al. 2006), and this was 
found to be the case in Samson et al.’s ApcLoxP/LoxP;MycLoxP/LoxP mice. Therefore, one 
can conclude that Myc is essential for the cellular and molecular changes which occur 




1.2.3 Expression of Apc 
Previous expression studies have provided conflicting results as to where Apc is 
expressed in the embryonic brain. Particularly confusing are studies which predict 
neuronal expression of Apc protein using in situ hybridisation (Bhat et al. 1994), and 
immunohistochemical studies that found intense labelling of oligodendrocytes without 
discernible neuronal staining (Bhat et al. 1996). A subsequent study was carried out 
by Brakeman et al. (1999) to try to clarify the Apc expression pattern. They found that 
Apc is expressed at high levels in neuronal cell bodies, dendrites and axons. The 
staining was particularly intense in neuronal layers of the hippocampus, olfactory bulb 
and cerebellum (Brakeman et al. 1999). This result is again controversial as another 
group (Senda et al. 1998) reported Apc expression in astrocytes as well as neurons.  
 
 
1.2.4 Apc 2 
A second Apc protein called Apc2 (previously known as ApcL), has been identified 
and is closely related to Apc. Since its discovery in by Nakagawa et al. (1998), Apc2 
has been shown to be broadly expressed throughout embryonic development in 
Drosophila (McCartney et al. 1999; Yu et al. 1999), as well as in humans (Nakagawa 
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et al. 1998) and rodents (Yamanaka et al. 2001). Like Apc, Apc2 has been shown to 
function within the Wnt signalling pathway to deplete levels of β-catenin (Nakagawa 
et al. 1998), as well as being involved in actin-associated events to influence cell 
motility or adhesion (Jarrett et al. 2001). A study by Yamanaka et al. (2002) showed 
that in the mouse, Apc2 is expressed strongly not only in the CNS, but also in the 
peripheral nervous system (PNS). Expression was first detected by northern blot at 
E10 in the brain and high expression levels continue until P10, at which point levels 
decrease through to adulthood. Using in situ hybridisation, Apc2 was found to be 
predominantly expressed in postmitotic neurones of the cerebral cortex, the retina, 
and the cerebellum at embryonic stages. By early postnatal stages, expression had 
reduced significantly in the cortex and the retina, however, in the still developing 
cerebellum, there is still relatively high levels of expression in the external and 
internal germinal layers. In the adult mouse brain, there are many regions which 
express Apc2. Expression was detected in the hippocampus, the cerebral cortex, the 
midbrain, and the cerebellum (Yamanaka et al. 2002).  
 
The expression pattern of Apc2 is important in relation to this project as our aim was 
to mutate Apc in the brain and observe the effects this has. It is possible that Apc2 
could assume Apc’s role in areas where we have mutated Apc. For example, in 
Drosophila, Apc and Apc2 have been shown to play redundant roles in larval brain 
development through the Wg (Drosophila Wnt) pathway and outside the Wg pathway 
(Ahmed et al. 2002; Akong et al. 2002; Hamada & Bienz 2002). Akong et al. (2002) 
showed by using an Apc2 mutant, that although Apc2 is strongly expressed 
throughout the CNS in normal flies, it is not essential for brain development. The 
most likely explanation for this is that Apc, which is also expressed throughout the 
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larval nervous system, can compensate for the loss of Apc2. To test this, Akong et al. 
studied both Apc and Apc2 mutants individually, and then created a double mutant. 
They found that individually, mutations of Apc and Apc2 were not lethal and that the 
only noticeable abnormality was in the Apc mutants photoreceptors in the eyes which 
displayed inappropriate apoptosis. However Apc-/-;Apc2-/- double mutants were 
zygotically lethal, which lends weight to the hypothesis that when mutated 
individually, they can compensate for each other in cells where expression overlaps 
(Akong et al. 2002).  
 
Further, a study by Hayashi et al. (1997) found that mutant Drosophila embryos that 
lacked D-APC (Drosophila homolog of mammalian Apc) showed a wild type cuticle 
pattern. Failure to downregulate Arm (β-catenin homologue) normally results in a 
uniform ‘naked cuticular’ pattern, hence implying that D-Apc may not be an essential 
component of the wingless (Wnt homolog) pathway (Hayashi et al. 1997). Since Apc2 
seems to have areas of overlapping expression with Apc in rodents (Brakeman et al. 
1999; Yamanaka et al. 2002), and that D-Apc2 has been shown to have the ability to 
interact directly with Arm and negatively regulate wingless signalling in the 
embryonic epidermis (McCartney et al. 1999), it is therefore very likely that Apc2 can 




1.3 Wnt Signalling 
1.3.1 Wnt signalling in CNS Development 
Wnt signalling has been implicated in all the crucial stages in CNS development: 
induction, patterning, expansion/proliferation, differentiation/migration, and 
synaptogenesis. For reviews, see Ciani & Salinas (2005); Kiecker & Niehrs (2001) 
and Stern et al. (2001). 
 
1.3.1.1 Induction and Patterning 
A study by Ikeya et al. (1997) looked at Wnt1 and Wnt3a signalling in the developing 
CNS. They did this by generating compound mutant mice lacking Wnt1 and Wnt3a. 
Briefly, their results demonstrate that in the absence of Wnt1 and Wnt3a, there is a 
marked deficiency in neural crest derivatives, and a pronounced reduction in 
dorsolateral neural precursors within the neural tube. This study suggests that Wnt 
signalling regulates dorsoventral patterning in the mammalian CNS through the 
control of cell proliferation (Ikeya et al. 1997). 
  
Further, a study by Houart et al. (2002) suggests that local antagonism of Wnt 
signalling in the anterior ectoderm of the anterior neural plate (ANB) is required to 
establish the telencephalon of zebrafish (Houart et al. 2002). This study ties in with a 
more recent one by Lagutin et al. (2003) who inactivated Six3 (a direct inhibitor of 
Wnt1 transcription), and found that the resultant mice had no forebrain. It could be 
concluded from this study that a Wnt signal gradient specifies posterior fates in the 




1.3.1.2 Expansion/Proliferation and Differentiation/Migration 
A study by Chenn and Walsh (2002) indirectly shows that disrupting Wnt signalling 
by overexpressing β-catenin in mice causes grossly enlarged brains with a 
considerable increase in surface area and thickness of the cerebral cortex. The main 
conclusion drawn form this paper is that β-catenin can function in the decision of 
precursors to proliferate or differentiate during mammalian neuronal development 
(Chenn & Walsh 2002). However, this is not direct evidence that Wnt signalling is 
involved in these stages of CNS development as: 1) β-catenin has other functions 
outside the Wnt pathway, so the overproliferation observed in the mutant mice may 
not be caused by β-catenin signalling through the Wnt pathway. 2) They created a 
mutant form of β-catenin which cannot be marked for destruction by the Apc/GSK-
3β/axin complex, therefore it is very possible that this has disrupted some of β-
catenin’s other functions outside the Wnt pathway. However, since β-catenin (acting 
in the Wnt pathway) regulates genes known to be responsible for cell growth and 
differentiation (ie c-myc and cyclinD1) it is very possible that the mutant β-catenin is 
acting through the Wnt signalling pathway to cause gross overproliferation in the 




A study by Hall et al. (2000) demonstrated that Wnt-7a was responsible for 
synaptogenesis in the cerebellum. Briefly, when they introduced a Wnt antagonist to 
cultured granule cell axons they found that the axon remodelling ability of granule 
cells was lost. They then added sFRP-1 (secreted frizzled related protein, a Wnt7a 
antagonist) found that simpler, less mature glomerular rosettes formed. The main 
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conclusion drawn from this study is that Wnt-7a, produced by granule cells, acts as a 
synaptogenic factor in vivo by regulating axon morphology and the accumulation of 
synaptic proteins (Hall et al. 2000). 
 
 
1.4 Development of the cerebellum 
 
To understand how medulloblastomas form in the cerebellum, and from what cell 
type, first we need to understand how the cerebellum forms during development (For 
review, see Wang & Zoghbi (2001). The cerebellum develops from the dorsal region 
of the posterior neural tube. The embryonic cerebellum begins as symmetric bulges 
into the fourth ventricle: cerebellar hemispheres arise as buds from laminae on either 
side of the rhombencephalic midline, and the most rostral segment of the 
metencephalon provides outgrowths that form the first elements of the cerebellum. 
These lateral sections develop towards the midline and fuse, forming the superior and 
inferior vermis. The lateral elements from this fusion develop into the cerebellar 
hemispheres. 
 
The cerebellum is made up of various cell types: granule, purkinje, stellate, basket and 
golgi cells and glia. The granule cells are glutamate – releasing, excitatory neurones, 
whereas the purkinje cells are inhibitory cells, using  as their transmitter. The other 
three are interneurons, found in the molecular layer of the cerebellum, which have a 
modulatory action on the purkinje cells and granule neurones (Wang & Zoghbi 2001).  
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The cells of the cerebellum arise from two different germinal matrices. The 
ventricular zone (also known as the ventricular germinal matrix) firstly gives rise to 
cells that radiate laterally and evolve into the deep cerebellar nuclei and purkinje cells 
of the cerebellum. The interneurons (stellate, basket and golgi cells) are born in the 
ventricular zone after the purkinje cells. These neurones migrate to the molecular 
layer of the cerebellum. The second germinal matrix that gives rise to cerebellar cells 
is an area called the rhombic lip. The rhombic lip arises relatively late in development 
at the interface between the neural tube and the roofplate of the fourth ventricle 
(Wingate 2001).  The rhombic lip produces granule cell precursors which migrate 
away from the rhombic lip and populate the EGL. From the EGL, a second zone of 
proliferation, the granule cell precursors migrate deeper into the cortex where they 
differentiate into mature granule cells.   
 
Once developed, the cerebellum’s main role is to control the execution of smooth 
coordinated movements. The cerebellum is composed of predominantly purkinje cells 
and granule cells which are arranged in a laminar array (Palay et al. 1974). Granule 
cell parallel fibre excitation and ascending axonal inhibition of purkinje cells are the 
principal elements of cerebellar circuitry (Bower 2002). The Purkinje cells 
communicate with the thalamus, brainstem and spinal cord by projecting efferent 
fibres which act as the sole output of the cerebellar cortex (Cholley et al. 1989; Teune 






1.4.1 Genes involved in development of cerebellum 
Patterning of the mid/hindbrain region from the neural tube is largely controlled by 
the isthmus organiser (IO) which is located at the border between these two regions. 
The IO is set up in a large part by the reciprocal expression of the genes Gbx2 and 
Otx2. Otx2 is expressed form E7.5 in the mesencephalon with its posterior boundary 
at the rostral metencephalon, whereas Gbx2 is expressed in the caudal 
mesencephalon. In addition to helping form the IO, Otx2 and Gbx2 regulate 
expression of Fgf8, with Otx2 repressing Fgf8 and Gbx2 maintaining it (Broccoli et 
al. 1999; Wassarman et al. 1997). Fgf8 is essential for normal midbrain development 
as Meyers et al. (1998) showed by creating a hypomorphic allele of Fgf8, which 
displayed severe patterning defects in the mid/hindbrain region which also affected 
the cerebellum (Meyers et al. 1998). Fgf8 is known to lie upstream of the Wnt 
signalling pathway, and in this mid/hindbrain region, it induces expression of Wnt1. 
Wnt1 in turn maintains expression of En1 which completes a feedback loop by 
positively regulating expression of Fgf8 (Simeone 2000). Other genes which are 
important for patterning this mid/hindbrain region are Pax2 and Pax5. Pax5 mutants 
only show a mild phenotype (Urbanek et al. 1997), however, Pax2-null mutant mice 
do not develop a posterior mesencephalon or cerebellum (Favor et al. 1996). A recent 
study by (Gao et al. 2007) showed the importance of Lim1b in patterning of this area 
by creating Lim1b-/- mutant embryos which displayed abnormal Wnt1, Fgf8, En1, and 
Gbx2 expression patterns. As a result of this, development of the cerebellum and 
tectum were severely impaired.  
 
At the rhombic lip, the bHLH transcription factor Math1 plays an important role in 
patterning. Indeed, a null mutation of Math1 in this area halts both precursor 
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differentiation and migration leading to a complete loss of the cerebellar granule cell 
layer and hindbrain mossy fibre afferent nuclei (Wingate 2005).  
 
In the cerebellum itself, there is a zone of proliferation in the EGL which has similar 
characteristics to the proliferative neural crest cells. Proliferation in these cells is 
known to be regulated by Wnts (Garcia-Castro et al. 2002), coupled with the fact that 
Wnt1 is expressed in precerebellar progenitor cells of the rhombic lip (Rodriguez & 
Dymecki 2000), it is very possible that Wnt signalling is plays a role in proliferation 
in these granule cell precursor cells. 
 
Shh (acting through Ptch) is also thought to play a vital role in normal cerebellar 
development, and in particular, in regulating EGL progenitor cells (Wechsler-Reya & 
Scott 2001). Purkinje cells are the main producers of Shh during cerebellar 
development (Marino 2005), and if Shh is blocked by using antibodies against Shh, 
then numbers of differentiated granule cells are reduced (Dahmane & Ruiz i Altaba 
1999). This effect of Shh on granule cell precursors is thought to be mediated through 
Shh’s role in cell cycle control. Shh induced cyclinD1 and cyclinD2 expression during 
development (Ciemerych et al. 2002) through N-myc (Kenney & Rowitch 2000).  
Mice lacking either N-myc or cyclinD2 display disorganised cerebellums and fewer 




1.5 Conditional gene targeting of Apc in the brain 
 
Conditional gene targeting is a method for mutating a gene of interest in vivo. This 
approach is very useful, for example in the case of Apc, where a constitutive knockout 
approach causes embryonic lethality, as well as evaluating the effects of mutating a 
gene in a specific tissue at a specific time. One of the most widely used methods of 




1.5.1 The Cre/loxP system 
The Cre/loxP system allows for the inactivation of the target gene in a single cell type, 
thereby allowing the analysis of physiological and pathophysiological consequences 
of the genetic alteration in mature animals. Cre recombinase is a 38-kDa protein 
encoded by bacteriophage P1. Its roles in the life cycle of P1 are thought to include 
cyclisation of the linear genome and resolution of chromosomes following DNA 
replication. A single Cre protein is sufficient to catalyse the recombination between 
two loxP (locus of X-over in P1) sites, each of which is a 34bp DNA sequence 
containing two 13bp inverted repeats and an asymmetric 8pb spacer region (Stricklett 
et al. 1999). Cre recombinase expressed ectopically in mammalian cells can cause 
either deletion or inversion of the sequences which are flanked by loxP sites, 
depending on the orientation of the loxP sites (Sauer & Henderson 1988). The main 
advantage of this system lies in its simplicity. For example, no cofactors are required 
for Cre activity because the Cre/loxP complex forms phosphotyrosine intermediates at 
the point of strand exchange which provides the necessary energy (Abremski & Hoess 
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1984). Another advantage is that the loxP target sites are small and easily synthesised 
and Cre recombinase is a stable protein (Stricklett et al. 1999). Finally, a great 
advantage of the system is that it is relatively easy to generate DNA constructs with a 
promoter of interest to drive the Cre expression. This last advantage however, can 
also lead to the main disadvantage of the Cre/loxP system. For example, in the case of 
this project, we wanted to mutate Apc specifically in the EGL of the cerebellum at P4 
of development. We had a floxed Apc mouse which expressed loxP sites flanking 
exon 14 of Apc, however, we were unable to identify a suitable gene to act as a 
promoter for Cre which was expressed specifically at our desired time and place. This 
led us to look for alternative ways to use the Cre/loxP system to mutate Apc.  
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1.5.2 The Adenovirus-Cre system 
Adenoviral vectors have been used for some time for introducing heterologous gene 
expression in mammalian cells (Berkner 1992; Prevec et al. 1991).  They have many 
advantages, for instance, they can infect a wide variety of dividing or non-dividing 
cells, they can be purified to high titres, they can accommodate up to 36 kb of foreign 
genetic material (Parks et al. 1996), to name a few. An adenovirion is a non-
enveloped icosahedral capsid with an approximate size of 700nm (Graham 2000) 
(Figure 4.1A). They contain protein and linear double-stranded DNA of around 30-
40kb in size. DNA replication and virion assembly takes place inside the nucleus, 
producing many thousands of virion before exiting and killing the host cell. 
 
For the transduction of mammalian cells, viral vectors under the control of promoter 
elements derived from viruses have been commonly used to date. One of the most 
frequently used promoters in these expression cassettes is that of the human 
cytomegalovirus (HCMV) immediate early (IE) gene. The HCMV enhancer/promoter 
directs high levels of transgene expression in a wide variety of cell types (Schmidt et 
al. 1990). More recent adenovirus vectors have been produced which used the murine 
cytomegalovirus (MCMV) IE promoter element. Indeed, Addison et al (1997) created 
such an adenovirus which when compared to an adenovirus driven by the HMCV 
promoter, was shown to drive higher transgene expression in vivo in mice and rats 
(Addison et al. 1997), indicating that Ad vectors carrying the MCMV IE promoter 
may be more effective than those with the HCMV IE promoter for transgene 
expression in animal models. 
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Adenoviral vectors are commonly created with deletions of the early regions 1 and 3 
(E1 and E3) (Danthinne & Imperiale 2000).  The E3 region is not essential so can be 
deleted without hindering the virus’s ability to replicate, however E1 region is 
essential for replication so if deleted, can only be propagated in vitro in cells that 
express E1 (Graham 2000). Such adenoviruses produced by deleting regions E1 and 
or E3 are known as First Generation (FG) vectors. FG vectors are useful for 
applications that require transient gene expression, however are not suitable for long- 
term expression since they retain most of their viral genes and express them at low 
levels causing host immune response in vivo. 
 
Cre-expressing adenoviral vectors have been extensively used in the mouse for 
targeting a variety of tissues such as the intestine (Shibata et al. 1997), the liver 
(Akagi et al. 1997; Chang et al. 1999; Stec et al. 1999; Wang et al. 1996), the brain 
(Wang et al. 1996) and in tumours (Sato et al. 1998). These studies have shown that 
this system for delivering Cre-recombinase in a spatial and temporal manner is very 
effective. However, there are drawbacks to the system. The main drawback is that 
adenoviruses, once injected into an area will infect all cells in that area. This is a 
problem for studies that require delivery of Cre-recombinase directly to specific cell 
types in, for example, the CNS. Further, adenoviruses are known to be able to infect 
many different cell types, however not all are equally well infected by the vector 
(Wang et al. 1996). Another drawback is that complications can arise from using E1 
deleted adenoviruses from the expression of viral functions on the vector genomes 
resulting in host immune response and loss of transduced cells (Badorf et al. 2002). 
Moreover, incorporation of tissue-specific promoters in first generation adenoviral 
vectors often results in loss of specificity because of viral elements influencing the 
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promoter activity (Badorf et al. 2002). Lastly, as will be discussed in a later chapter, 
delivery of the adenovirus can be problematic. For example, in the case of delivery of 
an adenovirus to the CNS, one must be very careful not to damage the brain through 
careless injection technique.  
 
1.5.3 The RCAS/tv-a system 
Retroviruses are capable of infecting target cells and introducing new genetic 
information into the chromosomes of these cells. Thus they can be used as vehicles 
for the delivery of genes into cells. A commonly used retrovirus is the avian leukosis-
A virus, RCAS (replication competent ASLV long terminal repeat with splice 
acceptor). RCAS was derived from RSV-A (Rous sarcoma virus-A) by the 
replacement of the src gene with a multicloning site that stably accommodates inserts 
of up to 2.5kb (Boerkoel et al. 1993; Greenhouse et al. 1988). These vectors are very 
widely used for gene transfer because they are replication competent viruses only in 
avian cells, and high titre viral stocks can be produced without a helper component 
(Orsulic 2002).   
 
The cloning of the tv-a gene in 1993, which encodes for the receptor for ALV-A, 
called TVA (Bates et al. 1993), has made it possible for RCAS vectors to be used in 
mammalian hosts such as mice. The receptor is a membrane-associated protein with 
homology to the ligand-binding repeat of the low-density lipoprotein receptor 
(LDLR). It was demonstrated that the ectopic expression of tv-a in mammalian cells, 
allows for entry and chromosomal integration by ALV-A (Bates et al. 1993). Without 
the expression of tv-a in the host, the ALV-A viruses would not be able to enter cells.   
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The advantage that the RCAS/tv-a transgenic system in mice has over avian uses of 
the RCAS virus is that the TVA receptor can be expressed under the control of a cell 
or tissue specific promoter. For example, only mouse cells that have been manipulated 
to express the TVA receptor can be infected; whereas mouse cells that do not express 
tv-a are resistant to RCAS infection. Once inside the cell, RCAS virus synthesises a 
DNA copy of the viral genome and integrates this into the host DNA. Once 
integrated, the expression of the inserted gene is driven by the viral long terminal 
repeat (LTR), giving a high level of transcription of the integrated provirus (Orsulic 
2002). Further, the lack of viral protein production prevents cell-to-cell spreading of 
infection, thus reducing any host immune response (Pinto et al. 2000).  
 
There are a few disadvantages however to using this avian system for genetic 
manipulation. For example, when introducing the RCAS virus into an appropriate tv-a 
expressing host, one has no control over the site at which integration of viral DNA 
occurs. In a worst-case scenario, the viral DNA could integrate in the proximity of an 
oncogene and lead to oncogenesis. Another issue is that the efficiency of the infection 
is dependent upon the accessibility of the organ and the proliferation rate of the target 
cells, as cell division is required for efficient viral integration (Orsulic 2002). A 
further disadvantage of using this method over traditional adenovirus methods is the 
necessity of producing a line of mice expressing the tv-a gene. This process adds 






1.6 Aims of thesis 
 
The central aim to this thesis was to assess the role of Apc in the development of 
medulloblastoma.  Our goal was to create a mouse model for medulloblastoma by 
conditionally inactivating Apc specifically in the cerebellum of P4 mice firstly by 
using the Cre/LoxP systen in combination with the RCAS/tv-a to administer Cre-
recombinase, and then when that method was unsuccessful, we used an alernative 
method of administering cre to ApcLoxP/LoxP mice using an adenovirus. A secondary 
aim of this thesis was to study the role of Apc in normal development in the mid-
hindbrain region, an area from which cells migrate from to populate the cerebellum. 
We did this by crossing the ApcLoxP/LoxP mouse to the En1-cre mouse. This was 
addressed as medulloblastoma is thought of as an embryonal tumour, which arises 
from cerebellar granule cell precursors, and that dysregulation of normal 
developmental pathways are involved in medulloblastoma development.  
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2. MATERIALS AND METHODS 
 
2.1 Methodology for Basic Cloning  
2.1.1 Agarose gel electrophoresis using DNA 
Agarose gel concentrations used varied from 0.5% to 2% w/v in Tris-borate EDTA 
(TBE) depending on the size of the DNA molecules. An appropriate mass of agarose 
powder was boiled (BioWhittaker Molecular Applications) in TBE buffer until 
dissolved and 0.1mg/ml ethidium bromide (EtBr)(Fisher Scientific) was added. DNA 
samples (volumes ranged from 2-50µl) were mixed with one-sixth volume of type III 
loading buffer (see Appendix for all solutions and reagents) and loaded onto the gel. 
Molecular weight markers were run adjacent to DNA samples. They comprised of 
1Kb or 100bp (New England Biolabs) and were diluted in loading buffer. 
Electrophoresis was carried out in 1X TBE at 50-100V for periods of 25 minutes to 3 
hours, with the exception of genomic DNA which was performed at 40 Volts for 12 
hours. Gels were visualised using UV light on a transilluminator.  
 
2.1.2 Restriction endonuclease digestion of DNA 
Plasmid DNA (1µg-5µg) was mixed with 0.1 volumes of 10X reaction buffer, 0.1 
volumes of appropriate restriction endonuclease, and the volume made up to 20-50µl 
with ddH20.  The digests were incubated in a shaking water bath set to 37°C for 90 
minutes. Genomic DNA was digested as above except that digests were incubated at 
37°C overnight to allow for complete digestion of genomic DNA. All restriction 




2.1.3 Extraction of DNA fragments from agarose gels 
The QIAquickTMGel Extraction Kit (Quiagen) was used for the extraction of DNA 
fragments from agarose gels.  DNA was digested with restriction endonucleases and 
electrophoresed on an agarose-TBE gel stained with ethidium bromide. A clean 
scalpel was then used to excise the DNA from the gel.  The gel slice was weighed and 
3 volumes of Buffer QG were added (eg. 100µl of buffer QG per 100mg of gel). The 
solution was heated to 50°C until the gel had dissolved completely. One gel volume 
of isopropanol was added to the solution, mixed, and applied to a Quiaquick spin 
column and centrifuged for 1 minute at 13 000rpm. To wash the DNA, 0.75ml of 
buffer PE was added to the column, centrifuged for 1 minute at 13 000rpm and the 
flow-through again discarded. To remove the last traces of buffer PE, the column was 
centrifuged once more then placed in a 1.5ml eppendorf tube. 30µl of water was then 
added to the centre of the column and the column allowed to stand at room 
temperature for 1 minute. The DNA was eluted by centrifugation at 13 000rpm for 1 
minute and the elute then transferred to a fresh 1.5ml eppendorf tube. DNA 
concentration could then be determined by electrophresis and either used immediately 
or stored at -20°C.  
 
 
2.1.4 DNA ligation 
DNA to be used as an insert in a ligation reaction was first purified by agarose gel 
electrophoreses and quantified on an agarose gel. An approximate 3-5 fold molar 
excess of insert DNA was added to vector DNA (10-15ng/µl) and diluted to 8µl with 
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water. 1µl of 10 ligation buffer was added to the solution followed by 1µl T4 DNA 
ligase (1 U/µl; Boehringer Mannheim). The solution was then incubated at 40C 
overnight.  
 
2.1.5 Transformation of competent bacteria 
For routine transformations DH5α E.coli cells were used. 200µl aliquots were 
removed from -800C storage and thawed on ice in a 12ml snap top Falcon 2059 tube. 
5µl of plasmid DNA was added directly to the cells and then the tube was tapped 
gently to mix. The cells and DNA were incubated on ice for 30 mintes, then heat-
shocked in a water bath set to 420C for 60 seconds, and returned straight onto ice. 
500µl of room temperature 2XTY media was added before shaking the tubes at 370C 
for 1 hour in a shaking incubator at 225rpm. The transformed bacteria were plated 
onto LB-agar plates containing appropriate antibiotics to select for transformants. 
Plates were inverted and incubated overnight at 370C. For all other transformation 
reactions, aliquots of JM109 competent E.coli cells (Promega) were used. 
Transformation protocol was as above except that the heat-shock duration was 30 




2.1.6 Mini and Midipreps 
For small scale preparations of plasmid DNA, a QUIAGEN QIA prep Spin Miniprep 
kit was used to purify the plasmid DNA from the transformed bacterial cells. A single 
bacterial clone was picked using a sterile yellow pipette tip. The clone was transferred 
to a falcon 2059 tube containing 1.5ml of LB medium supplemented with appropriate 
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antibiotics. This was then incubated overnight at 370C in a shaking incubator 
(225rpm). The next day, the bacterial culture was poured into a 1.5ml eppendorf 
microcentrifuge tube and spun at 13,000 rpm for 1 minute. The supernatant was 
discarded and the bacterial pellets were resuspended in 250µl of resuspension buffer 
(50mM Tris-HCl pH7.5, 10mM EDTA, 100g/ml RNase A). 250µl of bacterial lysis 
solution (0.2M NaOH, 35mM SDS) was added, and mixed by inversion to lyse the 
cells. The reaction was then neutralised by adding 350µl of neutralisation buffer 
(1.32M potassium acetate pH4.8) and mixed by inversion. The protein precipitate 
which subsequently forms was removed by centrifugation for 10 minutes at 13 000 
rpm. The supernatant was transferred to a QIASpin filter tube and placed in a 
collection tube and the liquid was passed through the filter by centrifugation for 1 
minute at 13 000 rpm. 750µl of wash buffer (80mM potassium acetate, 8.3mM Tris-
HCl pH 7.5, 40M EDTA, 55% (v/v) ethanol) was added to the QIASpin filter tube 
and then centrifuged for 1 minute at 13 000 rpm. To remove all the wash buffer, the 
collection tube was emptied and the filter tubes spun again for 1 minute at 13 000 
rpm. The filter tube was then placed in a fresh 1.5ml eppendorf before adding 50µl of 
water. The tube was incubated at room temperature for 1 minute and then spun for 1 
minute at 13 000 rpm. The eluted DNA was either used immediately or stored at -
200C. 
 
To achieve greater quantities of DNA than could be produced by the miniprep 
method, midipreps were carried out using the Quiagen Plasmid Midi Kit. A conical 
flask containing 50ml of LB or 2XTY medium, supplemented with appropriate 
antibiotics, was inoculated with bacteria created from a suitable miniprep culture. The 
bacteria was shaken at 225 rpm at 370C for 12 – 16 hours. The culture was then 
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centrifuged at 6 000g for 5 minutes at 40C, and the supernatant removed. The cells 
were re-suspended, lysed and neutralised using the same solutions as for the miniprep 
method. The protein precipitate was removed by centrifugation at 20 000g for 30 
minutes at 40C. Supernatant was removed and re-centrifuged at 20 000g for 15 
minutes at 40C, then added directly to equilibrated QIAGEN-tips, and allowed to pass 
through the DNA binding resin by gravity flow. Columns with bound DNA were 
washed with the supplied wash buffer (as above) twice prior to elution of the DNA. 
DNA was removed from the column using the supplied elution buffer (as above) 
before the addition of 0.7 volumes of isopropanol. The DNA was collected by 
centrifugation at 15 000g for 30 minutes at 40C. 70% ethanol was used to wash the 
DNA pellet before re-centrifugation for 1 minute at 13 000 rpm. The DNA pellet was 
re-suspended in 100µl of water and either stored at -200C or used immediately. 
 
2.2 Dissecting mouse tissue for histological analysis 
 
2.2.1 Harvesting embryos 
The mother was humanely killed by cervical dislocation and the embryos were 
dissected out in ice cold PBS before being placed directly into 4% PFA overnight. For 
embryos older than E15.5, the heads were removed and the bodies discarded to ensure 
that the PFA could penetrate the brain tissue more effectively. After fixation, the 
embryos were washed 3 times in PBS for 5 minutes each with shaking before being 
placed in 50% ethanol ready for processing and embedding in paraffin blocks. The 




2.2.2 Harvesting postnatal mouse brains 
Mice were perfused with 4% PFA and the skulls removed before removing the brain 
from the head. Depending on what the tissue was for, either the whole brain was 
placed into 4% PFA overnight, or the cerebellum was removed and placed into 4% 
PFA fix overnight. The tissue was then washed and processed as above. 
 
2.3 Histological analysis 
 
10µm sections were cut from paraffin embedded tissue and floated onto Poly-L-
Lysine (Sigma) coated slides in a water bath set to 420C. Slides were then stained with 
haematoxylin and eosin for histological analysis.  
 
 
2.4 Immunohistochemistry  
 
Immunohistochemistry was carried out using the DAKO envision plus system (cat. # 
K4006 for mouse kit and K4010 for rabbit kit) and performed using the manufacturers 
guidelines. β-catenin was detected using a mouse monoclonal antibody (BD 
Biosciences cat. # 610154) (see appendix for protocol) using the mouse DAKO 
envision kit. These kits come with a peroxidase blocking solution, and a peroxidase 
labelled polymer conjugated to goat anti-mouse immunoglobulins. Staining is 
visualised with 3,3’-diaminobenzidine (DAB) + substrate-chromagen which results in 
a brown-coloured precipitate forming at the antigen site. 
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Slides were dewaxed in xyline and rehydrated in an alcohol series before being placed 
in ddH2O. Antigen retrieval was carried out in 10mM Na-Citrate buffer, pH 6, and the 
slides were microwaved three times at 700W for 5 minutes each and cooled on ice for 
20 minutes. The slides were washed in ddH2O, incubated in peroxidase block for 5 
minutes before being rinsed in ddH2O and then placed into PBS for 5 minutes. Slides 
were incubated in antibody buffer (1 in 5 dilution of goat serum in PBS) for 10 
minutes before the addition of primary antibody at an optimal concentration of 1 in 
100 dilution for 1 hour at room temperature. Slides were thoroughly rinsed in ddH2O 
and incubated in HRP anti-mouse secondary antibody for 30 minutes at room 
temperature. Slides were thoroughly washed in ddH2O before the addition of DAB 
solution. Once appropriate staining had occurred, the DAB solution was washed off 
with ddH2O, counterstained with haematoxylin and then dehydrated through an 
alcohol series, cleared in xyline and mounted using DPX mounting media (Sigma). 
See appendix (Section 8.2.2) for a detailed protocol. 
 
Apc was detected using an Apc C-terminal rabbit polyclonal primary antibody (Santa 
Cruz cat. # sc896) (see appendix for protocol), and the DAKO envision plus rabbit 
kit. The protocol was as above except all washes were carried out three times for 5 
minutes each with PBSTx  in an effort to reduce background staining. Antigen 
retrieval was carried out in10mM Na-citrate 4 times for 5 minutes in a 700W 
microwave. The primary antibody was titrated and used at an optimal concentration of 




Nestin immunohistochemistry was carried out using identical conditions to those of 
the β-catenin immunohistochemistry (see appendix for protocol, section 8.2.2) except 
a Nestin antibody was used at a concentration of 1:200 in antibody buffer. 
 
Pax 3 immunohistochemistry was carried out using identical conditions to those of the 
Apc immunohistochemistry (see appendix for protocol, section 8.2.1) except a Pax 3 
antibody was used at a concentration of 1:100 in antibody buffer. 
 
 
2.5 Tissue Culture 
 
2.5.1 DF-1 cells 
DF-1 cells were stored at -800C in CryoTubeTM vials (Nunc) and were thawed with 
gentle agitation in a water bath prewarmed to 370C. The cell suspensions were then 
dispersed into 25ml of DMEM culture media (Gibco. Cat # 11960-044) supplemented 
with 10% (w/v) foetal calf serum (FCS), 20mM L-Glutamine (Sigma), 20U/ml 
Penicillin (Sigma) and 20µg/ml Streptomycin (Sigma). Cells were incubated at 370C 
in an atmosphere of 5% CO2 in Sanyo CO2 incubators. Cells were cultured in 
disposable sterile plasticware flasks and petri dishes (either Nalge-Nunc or Greiner). 
All media added to cells was sterile and prewarmed in a water bath to 370C. 
 
2.5.2 Trypsinisation of cells in a T75 flask 
The medium was aspirated off and the cells washed twice with 5 ml of PBS buffer to 
remove all the old media. The PBS was aspirated off before the addition of 1 ml 
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Trypsin solution. The flask was gently rocked so the typsin covered all the cells 
before being incubated at 370C for 2-3 minutes (or until cells started to come off the 
culture flask when gently tapped). 2 ml of culture medium was added to the flask 
using a pasture pipette and the solution drawn up and down the pipette several times 
to break up the clumps of cells and remove all the cells from the side of the flask. The 
liquid transferred to a 15ml centrifuge tube and made up to a volume of 10 ml by 
adding 8 ml fresh culture medium. The tube was centrifuged at 1000 rpm for 5 
minutes to create a pellet of cells at the bottom of the tube. The media was aspirated 
off and 10ml of PBS added before further centrifugation at 1000rpm for 5 minutes. 
The PBS was aspirated off and the bottom of the tube tapped to loosen the cells. The 
cells could either be re-suspended in fresh media and plated at a density of 2 x 106 
cells/ml or resuspended in freezing media to a concentration of 4 x 106 cells/ml and 
stored at -800C. 
 
2.5.3 Transfecting cells using GeneJuice transfection reagent 
Stably transfecting RCAS-cre and R26R plasmids into DF-1 cells was carried out 
using GeneJuice transfection reagent (Merck). 45µl of GeneJuice reagent was added 
to 800µl of serum free DMEM media in a sterile 1.5ml eppendorf. The contents were 
mixed by inversion and incubated at room temperature for 5 minutes. 15µl plasmid 
DNA was added and the contents mixed again and incubated for 15 minutes. This mix 
was then added evenly over sub-confluent DF-1 cells in a 10cm tissue culture petri 
dish containing DMEM supplemented with 10% FCS. The cells were then incubated 
for 5 hours at 370C. The transfection mix was then aspirated off and replaced with 
complete growth medium (lacking antibiotics). Cells were incubated for 2 days until 
confluence was reached. The virus was then titred by extracting the supernatant and 
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making a series of 10-fold dilutions of the viral supernatant (from 10o to 109) in 
growth medium. 1ml of each dilution was added to a 60 mm TC dish containing DF-1 
cells. Dishes were then incubated for 3 hours at 37oC. 2 ml of growth medium was 
added to each dish. Cells were allowed to grow for 4 to 7 days and assayed for gene 




2.5.4 Preparing RCAS containing DF-1 cells for injection into mice 
On day of experiment, RCAS containing DF-1 cells where trypsinised from T75 flask 
and a cell count was carried out to determine the number of cells in the flask. The 
cells were then resuspended in an appropriate volume of DMEM (lacking antibiotics) 
so that 1µl contained 1x104 RCAS containing DF-1 cells. This virus preparation was 
then aliquoted into eppendorfs. From this, 1µl containing 1x104 RCAS containing 
DF-1 cells was injected into the hindbrain region of 127 postnatal day 4 (P4) mice. 
 
 
2.6 Isolating stably transfected clones 
 
Cells which were successfully transfected with R26R plasmid carried antibiotic 
resistance so could be separated from non transfected clones by adding Geneticin 
(G418) Sulphate (Invitrogen). G418 was added at an optimal concentration of 
400µg/ml and incubated at 370C. Cells were checked each day and single colonies of 
cells were picked by applying 2µl of trypsin directly onto the colony and then 
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immediately drawing the cells into the pipette tip. The cells were transferred into a 96 
well tissue culture plate in 200µl complete growth media. Once confluent, cells were 




2.7 Isolating genomic DNA from mouse ear or tail 
biopsies 
 
For genotyping purposes, DNA was extracted from either ear clips or tail tips. 500µl 
of lysis buffer (TTLB) was added to the ear clips in a 1.5 ml eppendorf tube and 
incubated overnight at 550C in a shaking water bath. 300µl phenol chloroform was 
added and the mixture vortexed to mix before being incubated at room temperature 
for 5 minutes. The tubes were centrifuged at 13,000 rpm for 1 minute to leave an 
upper aqueous phase which was subsequently removed into a fresh 1.5ml eppendorf 
containing 2.5 volumes of 100% ethanol and 0.1 volumes of 3M NaOAc. The tubes 
were vortexed to mix and incubated for 30-60 minutes at -200C to allow the DNA to 
precipitate. The tubes were centrifuged at 13,000 rpm for 15 minutes to pellet the 
DNA and 200µl of ddH2O added to re-suspend the DNA if using ear clips. When 
using tail tips, 400µl ddH2O was used to re-suspend DNA. In order to remove all 
residual traces of ethanol, the tubes were incubated at 550C for 45 minutes on a PCR 
block with the caps left open to allow ethanol to evaporate. The samples were then 
vortexed and briefly centrifuged to collect the entire sample at the bottom of the tube. 
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The DNA could then be used directly in a genotyping PCR reaction, or stored at -
200C. 
 
2.8 Southern Blot 
 
2.8.1 Making Probe 
Probe used was designed based on Probe C described by Shibata et al. (1997) and is a 
1kb Hind III – Xba I fragment derived from exon 15 of Apc. Using primers which 
flanked the 1kb Hind III – Xba I fragment of Apc, PCR was used to create the desired 
probe from genomic DNA. The probe was then transformed in E.coli and purified 
with a midiprep.  
 
A restriction digest was then set up using 40µl of midiprep DNA with 5µl of EcoR1 
and 5µl of enzyme buffer and incubated at 370C overnight. The digest DNA was then 
run on an agarose gel before being cut out and gel purified. 
 
2.8.2 Making Southern quality DNA 
Tissue (eg half of cerebellum) was digested overnight at 550C in 500µl of TTLB with 
proteinase K. Equal volumes of phenol chloroform (500µl) was added to DNA and 
mixed by inverting for 10 minutes. The tubes were centrifuged at 13,000 rpm for 1 
minute to leave an upper aqueous phase which was subsequently removed into a fresh 
1.5ml eppendorf containing 2.5 volumes of 100% ethanol and 0.1 volumes of 3M 
NaOAc. Eppendorfs were shaken hard for a few seconds until a white precipitate 
formed. This precipitated DNA was removed from the solution and dipped in 70% 
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EtOH to clean before being put in a clean eppendorf. DNA was then left for 2-3 hours 
to dry before addition of 20µl of buffer TE. DNA was then re-suspended in a 370C 
shaking water bath overnight. Once the DNA had re-suspended, it was cut using a 
restriction digest containing 40µl DNA, 5µl 10x buffer, 2µl spermidine, and 2µl Sac I 
restriction enzyme. Digest was incubated overnight at 370C before the addition of 
10µl loading buffer. Samples were then run on an 0.8% maxi gel (containing no 
ethidium bromide) for 16 hours at 40V.  
 
The gel was ethidium bromide stained and images of the electrophoresed DNA were 
captured on a UV transilluminator for later comparison. Transfer of the DNA to the 
nylon membrane was improved by partial depurination (‘acid nick’) of the DNA prior 
to transfer.  Partial depurination was achieved by soaking the gel for 30 minutes in 
0.2M HCI. The gel was then soaked in 500ml of southern denaturation buffer for 30 
minutes to denature the DNA. After a brief rinse with water the gel was submerged in 
500ml of southern neutralisation buffer for 30 minutes.  Meanwhile a sheet of 
Hybond-N nylon membrane (Amersham Pharmacia Biotech) was briefly 
equilibrated in transfer buffer (10X SSC). DNA was transferred from the gel onto the 
membrane overnight.  The membrane was subsequently rinsed in 2XSSC, UV cross 
linked and baked at 120°C for 20 minutes.  Membranes were stored between sheets of 





The prepared membrane was rolled between two hybridisation meshes in a 
hybridisation tube (Hybaid) and 25mls of Church Hybridisation buffer, preheated to 
65°C, was added. Salmon sperm DNA was denatured for 5 minutes in a water bath set 
to 1000C and added to a final concentration of 0.1mg/ml to reduce background 
hybridisation. Membrane and buffer were incubated with rotation at 65°C for 3 hours 
in a hybridisation oven (Hybaid) to allow the membrane to equilibrate.  
 
2.8.4 Making radiolabelled probe 
25ng of clean probe DNA was made up to 45µl with buffer TE and added on top of 
the labelling mix (Rediprime II Random Probe Labelling System, Amersham 
Pharmacia). 5µl of 32P-dCTP was added and mixed by pipetting, and incubated at 
37°C for 10 minutes. The reaction was stopped by the addition of 5µl 0.2M EDTA 
(pH8). Labelled probe was separated from unincorporated nucleotides using a 
Sephadex G50 column (Amersham Pharmacia Biotech). The column is equilibrated 
by centrifugation at 3000rpm for 1 minute. The radiolabelled probe solution was 
added to the column, centrifuged at 3000rpm for 2 minutes and the elute containing 
the radiolabelled probe was collected in a 1.5ml Eppendorf tube. Unincorporated 
nucleotides remained in the column and it was discarded. The radiolabelled probe was 
denatured by placing in a hot block at 100°C for 10 minutes, and placed on ice. 
 
2.8.5 Hybridisation 
Following prehybridisation, the Church buffer was removed and 10mls of fresh 
church buffer, preheated to 65°C and containing salmon sperm DNA, was added to 
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the hybridisation tube. The radiolabelled probe was then added and the membrane 
was incubated with rotation overnight at 65°C.  The membrane was washed four 
times for 30 minutes each in Church Wash at 65°C. Following these washes the 
membrane was removed from the hybridisation tube, sealed in Saran wrap and 
exposed to MR X-ray film (Kodak) in an autoradiography cassette.  Autoradiography 
cassettes were stored at -70°C for 1-5 days, depending on signal strength.  




3. Deleting Apc in the early postnatal hindbrain 
using the RCAS/tv-a system 
 
3.1 Background 
With this experiment, our aims were to test the hypothesis that the loss of Apc on both 
chromosomes leads to MB development in mice. We used a variation of the Cre-loxP 
method of selectively mutating genes in a spatial and temporal manner.  
 
In an attempt to deliver Cre-recombinase, stage- and site- specifically, we utilised 
retroviruses. We decided on this approach because there was not an appropriate Cre 
strain of mouse available at that time. Ideally, we wanted a strain of mouse that 
expressed Cre-ER under the control of the nestin promoter and enhancer.  Cre-ER is a 
fusion of Cre and the mutated ligand-binding domain of the human oestrogen receptor 
α. Upon administration of tamoxifen, the Cre-ER is turned from an inactive state to 
an active one, which is capable of recombination (Imayoshi et al. 2006). 
Unfortunately, there was not an ideal Cre mouse strain available at the time, so we 
decided to use a retroviral method. Since the time of this experiment, Imayoshi et al. 
(2006) have generated a Nestin-CreER strain of mouse.  
 
To mutate Apc specifically in the hindbrain at early postnatal stages to create a mouse 
model for MB, we used the RCAS/tv-a system with an RCAS virus which expressed 
Cre-recombinase and green fluorescent protein (GFP) (Gift from Eric Holland, 
MSKCC) in infected cells, and a mouse strain which expresses the tv-a gene under the 
nestin promoter. Nestin is an intermediate filament protein, expression of which is 
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extensively used as a marker for CNS progenitor cells (Dahlstrand et al. 1995).  The 
nestin promoter was deemed to be the best promoter to drive expression of the tva 
gene, as it has been shown to be expressed in proliferating neural precursor cell 
populations with very high expression from E7.75 to E15.5, and reducing in its 
expression during the later part of neural development until P0 stage where its 
expression is restricted to the developing CB and the ventricular and subventricular 
areas of the telencephalon (Dahlstrand et al. 1995). From the literature, we would 
expect that MBs form in proliferating cells of the EGL of the postnatal cerebellum, 
and since these cells are neural precursor cells, we would expect them to express 
nestin. However, to date the expression of nestin has not been published in enough 
detail for us to be sure of its exact expression pattern at postnatal day 4, when we 
ideally wanted to mutate Apc. Therefore, immunohistochemistry for the nestin protein 
was carried out to ascertain the exact expression of nestin in the CB at P4.  
 
3.2 Results 
3.2.1 Nestin expression 
We removed the brains from P4 wild-type CBAxBl 6 F1 mice and fixed them in 
paraformaldehyde. They were embedded in wax and cut in a sagittal plane. 
Immunohistochemistry was then performed using the nestin primary antibody as 
described in the materials and methods section. Figure 3.1 shows nestin expression in 
the filaments of these proliferating EGL cells of the cerebellum. No nestin expression 
was observed anywhere else in the CNS at this stage of development. 
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3.2.2 Apc expression 
For Apc to be mutated in the EGL of the cerebellum, it must be expressed in the EGL 
of the cerebellum. Therefore, we carried out immunohistochemistry using an Apc 
primary antibody. This experiment was necessary because previous studies of Apc 
expression in the CNS were not conclusive (see introduction section 1.2.3) and did 
not show a detailed expression pattern of Apc in the CB at P4 stage of development. 
The results of our Apc immunohistochemistry show that Apc is strongly expressed in 
the GCPs and throughout the cerebellum. (Figure 3.2)  
 
 
3.2.3 RCAS-Cre virus preparation 
Once it was established that both Apc and nestin were expressed in the expected 
patterns, we obtained an aliquot of the RCAS-Cre plasmid. This had to be propagated 
in E. coli  to produce a large midi prep stock. This DNA was then transiently 
transfected into DF-1 (chicken fibroblast) cells. Since the RCAS virus has the ability 
to replicate and infect other DF-1 cells, any successfully transfected DF-1 cell will 
produce RCAS-Cre virus and within a few days, will infect all the cells in the dish. 
The RCAS-Cre plasmid also carries GFP in the insert. This made it easy to test the 
trasfection efficiency as a sample of transfected cells could be grown on a poly-L-
lysine coated coverslip and observed under a fluorescent microscope. Under 
fluorescent light, cells expressing RCAS-Cre appear green and non-infected cells will 
be invisible. Figure 3.3 compares a white light picture to a fluorescent picture of 
transfected DF-1 cells. Although the picture quality is not perfect, when looking down 
the microscope, it could be observed that 100% of cells fluoresced green and therefore 
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3.2.4 Generation of experimental animals 
Mouse crosses were set up to create animals of the desired genotype (Ntv-a 
+;ApcLoxP/LoxP). A diagram of how the crosses were set up can be seen in Figure 3.4. 
1µl containing 1x104 RCAS containing DF-1 cells was injected into the hindbrain 
region of 127 postnatal day 4 (P4) mice. These mice were the progeny of a cross 
between an Ntv-a-;ApcLoxP/LoxP male and a Ntv-a+, ApcLoxP/+ female. The resultant 
progeny were expected to follow Mendelian genetics giving us 1 out of 4 animals of 
the desired genotype.  2 weeks after injection, the animals could be ear-punched for 
genotyping. Results of genotyping showed no animals of the desired genotype. The 
PCR genotyping was repeated with the same result. Our conclusion from this was that 
tv-a and Apc must be located on the same chromosome. This would necessitate a 
recombination event taking place for us to see our desired genotype (Figure 3.4B). If 
this recombination took place, then the reciprocal recombination genotype to Ntv-
a+;ApcLoxP/LoxP, which is Ntv-a - ;ApcLoxP/+, would also not be observed in any of the 
injected animals.  
 
Animals with the genotype is Ntv-a - ;ApcLoxP/+, would have been uninfectible with 
RCAS-Cre, and so were classed as a control. Mice with the genotype Ntv-a 
+;ApcLoxP/LoxP, we called our experimental group as these are the ones which would be 
infectible with RCAS-Cre, and were homozygous for the floxed Apc allele. The 
genotyping results showed that 4 out of the 127 RCAS-Cre injected animals had the 
control genotype (Ntv-a -;ApcLoxP/+) implicating that a recombination event had taken 
place. This gave us hope that the transgenes were relatively far apart on the 
chromosome making it possible for recombination events to take place. We reasoned 
that if we set up many crosses of animals with the genotypes as follows; Ntv-a +/-, 
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ApcLoxP/+ X ApcLoxP/LoxP, we would eventually get an animals with the desired 
experimental genotype (Ntv-a +;ApcLoxP/LoxP).  An additional advantage of creating 
such a recombinant mouse is that it would generate large numbers of suitable mice 
because the tv-a transgene would be fixed on the same chromosome as the floxed 
allele and would therefore be co-inherited at a high frequency.  
 
In total, 15 crosses were set up which produced 138 pups. When genotyped, no 
animals were found to have either of the recombinant genotypes. From this result, the 
validity original genotypes of the four recombinant animals were brought into 
question. When re-genotyped, the animals were found to actually have the genotype 
Ntv-a +;ApcLoxP/+ (not recombinants) (Figure 3.5). Therefore, out of 265 mice, none 
were found to have either the experimental or control recombinant genotypes. The 
null hypothesis would state that the resultant progeny were expected to follow 
Mendelian genetics giving us one out of four animals of the desired genotype (Figure 
3.4D). To test whether there was a high probability that our results could be due to 
chance, a chi-squared test was performed to compare the observed results against the 
expected result. The result of this test showed p< 0.001, hence we can reject the null 
hypothesis that the observed values of our cross are the same as the theoretical 
distribution of a 3:1 ratio.  
 
To approximately determine the distance between the Ntv-a and ApcLoxP alleles we can 
use the technique devised by T.H. Morgan, who was the first person to discover 
linkage. Indeed, the ratio of recombinants to non-recombinants can give an indication 
of the genetic distance between two loci. If 1 centimorgan equals 1% of 
recombination events which take place, and if 1 centimorgan also equals 1000 kilo 
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base pairs (kbp) in the mouse, we can work out that since we saw 0 recombination 










3.2.5 Analysis of RCAS/tv-a infected animals 
All of the 127 RCAS-Cre infected animals were left for a period of between 10 and 20 
weeks with no animals showing signs of brain tumours, such as lack of appetite, 
sluggish movement, swollen head etc. We let the animals live for as long as possible 
even though we knew that none had the desired genotype as there was a slight chance 
that one could spontaneously loose the second Apc allele and develop a tumour as we 
would expect to happen in the human condition. Eventually, all the animals had to be 
sacrificed as the animal unit they were housed in was closing. For each animal, the 
cerebellum was removed, cut in half along the midline with half being fixed with 
PFA, embedded in wax and a random selection of 10 brains were cut sagittally. DNA 
was extracted from the other half of the cerebella for use PCR analysis to test for loss 
of Apc. Of note, none of the mice showed any external signs of abnormalities before 
they were culled.  
 
Upon haematoxylin and eosin histological examination, the cerebella of the RCAS-
Cre infected animals were no different to that of wild-type control animals. (Figure 
3.6).  With regard to the PCR analysis, none of the 127 mice showed any sign of cre-









In conclusion, this experiment did not give us the expected result because we were 
unable to produce mice with the genotype (Ntv-a +;ApcLoxP/LoxP ) necessary to cause 
the deletion of both alleles of Apc when mice were infected with RCAS-cre. Our 
conclusion was that both Apc and tv-a must be on the same chromosome. We believed 
that we had four mice with the reciprocal recombinant genotype, which gave us hope 
that the Apc and tv-a were far enough apart on the chromosome to produce a 
recombination again. However, after an extensive breeding program we were unable 
to produce any more recombinant animals. When the original recombinant mouse 
DNA was retested, it was concluded that the mice were miss-genotyped. This was a 
problem as at the time, the PCR protocol for detecting Ntv-a was unreliable.  
 
We looked at the infected mice for histological abnormalities and found none 
compared to wild-type infected controls. When we also tested the DNA of infected 
Ntv-a +;ApcLoxP/+ heterozygotes, we did not detect any cre-mediated deletion of Apc 
via PCR. We would have expected to see a deleted band in RCAS-cre infected Ntv-a 
+;ApcLoxP/+ heterozygotes as one of the chromosomes should have been deleted. 
However, a possible explanation for this is that as only one chromosome would have 
been deleted, perhaps this was below the level of detection of the PCR.  
 
If more time had permitted, we would have conclusively tested whether Apc and tv-a 
were on the same choromosome by performing fluorescent in situ hybridisation 
(FISH). Apc and β-catenin immunohistochemistry could also be carried out to assess 
in more detail whether any cre mediated deletion of Apc had occurred and wheter the 
Wnt pathway was over stimulated. However, since so much time had been spent on 
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Once it became clear that we could not inactivate Apc in the granule cell precursor 
cells of the cerebellum using the RCAS/tv-a method, we switched an alternative 
strategy of using an adenovirus which expresses cre-recombinase (AdCre) and 
injecting it directly into the developing cerebellum of postnatal day 4 (P4) ApcLoxP/LoxP 
mice. The main downside to using an adenovirus was that the virus was expected to 
infect all cells around the injection site so would not be nearly as specific as the 
RCAS-cre virus. The advantage of the AdCre method over the RCAS/tv-a method 
was that we could inject the virus directly into our floxed Apc mice without the need 
for complicated, time-consuming and expensive breeding steps. We decided to 
purchase for our experiment the AdCreM2 adenovirus from Microbix.  The AdCreM2 
vector carries the cre recombinase encoding gene under the control of the murine 
cytomegalovirus (MCMV) immediate early gene promoter (Figure 4.1B). This first 
generation type of AdCre was selected for our use as the MCMV promoter has been 
shown to produce higher expression levels in almost all cells in the mouse compared 
with adenoviruses whose gene expression is driven by the human cytomegalovirus 
(HCMV) (Addison et al. 1997). From published work by Wang et al. (1996), we 
estimated that we needed to inject a very small volume (1µl) of highly concentrated 
(1x108pfu per µl) adenovirus. We could not find any supplier who could deliver 
AdCre at such a high concentration, so we bought a low concentration aliquot from 





To test whether the AdCre was infecting Apc expressing cells and that the cre-
recombinase was able to delete the floxed region of the Apc gene, we conducted a 
small-scale pilot experiment. Eight ApcLoxP/LoxP postnatal day 4 mice (the progeny of a 
male ApcLoxP/LoxP crossed to an ApcLoxP/LoxP female) were anaesthetised and injected 
with adenovirus-cre (AdCre) as with the RCAS/tv-a experiment. Infected mice were 
sacrificed at 3 days, 21days, and 5 weeks post infection. The cerebella were removed 
and the DNA was extracted to perform a PCR using primers that identified whether 
the exon 14 of the Apc gene had been deleted (Figure 4.1B). Figure 4.2 shows DNA 
from eight AdCre infected animals at various time points after infection, and two 
RCAS-cre infected animals as controls. From the gel, it is clear that deletion of exon 
14 of Apc to generate ApcLoxPΔ can be detected 3 days, 21 days, and 5 weeks post 
infection. No cre-mediated deletion was observed in the RCAS infected animals. 
Thus, the AdCreM2 virus is able to promote cre-mediated inactivation of the 
conditional ApcLoxP allele in early postnatal hindbrain. ApcLoxPΔ was detected as soon 
as three days post infection and was still detectable five weeks later, suggesting that 





From here we set up a larger scale experiment using a total of 94 mice injected with 
AdCre. Infections were carried out as with the RCAS/tv-a experiment, and culled at 
set time intervals (Figure 4.3) Animals were watched closely for any evidence of 
brain tumour formation such as lack of appetite, circling movements, lack of 
movement, swelling of the head etc. Seven mice out of the 94 infected showed these 
symptoms so were culled immediately and examined. All seven mice were found to 
be suffering from hydrocephaly and none had any evidence of brain tumour 
formation. The brains were fixed and embedded in wax to be cut for histological 
analysis and an example of one can be seen in Figure 4.4 which shows a 
hydrocephalic brain with characteristically enlarged ventricles and an enlarged fluid 
filled cerebellum. 
 
When mice were sacrificed the cerebella were bisected along the midline, with half 
being used for histological analysis, ie. stained with haematoxylin and eosin, and the 
DNA was extracted from the other half of the cerebellum for either Southern blots or 
PCR to identify whether or not Apc was successfully deleted. Samples shown by PCR 
to have strong Apc deletion were cut and stained for histological analysis. Figure 4.2B 
shows an example of the large scale PCRing that was carried out to determine which 
AdCre infected animals showed evidence of deletion of exon 14 of Apc. The primers 
used were based on those used by Shibata et al. (1997) and are shown 
diagrammatically in Figure 4.1C.  A full table of numbers of animals infected with 
their genotypes and how many animals showed cre-mediated deletion of exon 14 of 
Apc is shown in Figure 4.3. Southern blots were originally used in an attempt to 
evaluate which infected animals showed cre mediated deletion. The probe used was a 





This is the same probe that was used by Shibata et al. (1997) and the expected band 
sizes would be 12kb for the floxed Apc band, 8kb for the deleted band, and 7kb for 
the wild-type band. Figure 4.2C shows the only southern blot to produce a positive 
result. Other Southern blots which were attempted, either produced extremely high 
background or revealed no bands at all. I proceeded to troubleshoot the protocol by 
remaking the probes and solutions, used new hybond membrane, increasing the 
number of wash steps post hybridisation to reduce background, and varied the length 
of time the film was developed (between 1 and 5 days) to attempt to produce a clearer 
blot. However, after all of these attempts, I was unable to recreate the results I 
produced on my first Southern blot.  
 
Figure 4.2C shows some of the same samples as Figure 4.2A with two animals taken 
3 days post-infection, and three animals taken 21 days post-infection. Comparing 
Southern blot results with those from the PCR method for detecting cre-mediated 
deletion, the Southern blot method is less sensitive as only samples 1 and 4 show a 
deleted band with sample 5 possibly showing a very faint band.  
 
 
Our PCR screening for Apc deletion showed that AdCre virus must have been 
infecting cells and mutating Apc. We picked brains from mice which showed the 
strongest floxed-deleted Apc band from the PCRs, and cut serial sections sagittally 
through the cerebellum. However, no evidence of brain abnormalities were evident 
when comparing brains from mice showing Apc deletion when compared to controls 




It was hypothesised that only a very small amount of cre-mediated deletion was 
occurring. This would also explain why the Southern blot showed such a faint deleted 
bands as there were so few cells infected, it was probably below the threshold of 
detection for Southern blots. To test the efficiency of AdCre infection, we infected 8 
R26R reporter mice with our AdCre. These R26R mice are a transgenic strain in 
which a lacZ reporter gene is activated in response to cre-recombinase activity. 5 days 
after infection, we collected cerebella from infected R26R animals, cut sections and 
stained for lacZ activity. The results are shown in Figure 4.6. We found that only cells 
of the choroid plexus epithelium showed evidence of cre-mediated deletion. Since 
activation of lacZ should have no deleterious consequences for cells, this suggests that 
the tissue tropism of the virus was not as expected, accounting for the failure of 
AdCreM2-infected ApcLoxP/LoxP animals to show any abnormalities in the cerebellum. 
 
If more time had allowed, we would have performed Apc and β-catenin 
immunohistochemistry on these sections to categorically show that there was no loss 
of Apc expression in the cerebellum and that the Wnt signalling pathway was not 







This set of experiments aimed to produce a mouse with an Apc mutation specifically 
in the hindbrain at an early postnatal stage. As with the RCAS-cre experiment, which 
had the same goals, this was unsuccessful. None of our 87 AdCre infected animals 
displayed any histological abnormalities with the exception of the seven mice which 
developed hydrocephalus. Since we have shown that only cells of the choroid plexus 
were infected by the AdCre, and that defects in the choroid plexus could possibly to 
lead to hydrocephaly (Shin et al. 2006) the most likely explanation for this result is 
that Apc function was lost in these cells causing overproduction of cerebrospinal fluid 
(CSF). Since no mice infected with RCAS-cre displayed any sign of hydrocephaly, 
we ruled out the possibility that hydrocephaly was caused by damage done during the 
injection procedure. Adenovirus vectors injected into the brain can stimulate an 
inflammatory response (Cartmell et al. 1999). It is possible that the a localised 
immune reaction to the adenovirus could lead to cause swelling of the ventricles by 
immune cells crossing the blood brain barrier and entering the CNS parenchyma or 
ventricles. Another possibility is that adenovirus material may produce a meningeal 
irritation (Norrby et al. 1980) causing disturbances of the extraventricular flow or 
reabsorption of cerebrospinal fluid, leading to hydrocephalus. 
 
After a search of the literature, we decided that the AdCreM2 virus would be a good 
option for introducing cre-recombinase to the cerebellum. E1-deleted first generation 
AdCre vectors have been successfully used to mediate loxP – dependent 
recombination in vitro using cultured cells (Kanegae et al. 1995; Kanegae et al. 1996) 
and in vivo targeting cells in the liver (Chang et al. 1999; Wang et al. 1996), in 
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tumours (Addison et al. 1997; Sato et al. 1998) and in the brain (Wang et al. 1996). In 
the study by Wang et al. (1996), AdCre was injected into one hemisphere of the 
forebrain in newborn ApcLoxP/LoxP mice. Mice were sacrificed and genomic DNA was 
isolated from each hemisphere and subjected to PCR analysis. Cre-mediated 
recombination was detected in the injected hemispheres at all time points (Wang et al. 
1996). Our experiment seemed to fail mainly from the fact that our AdCre virus did 
not infect cells of the cerebellum, as was the intention, and instead only infected a 
very small population of cells in the choroid plexus of the 4th ventricle. The Wang et 
al. (1996) study clearly showed the ability of their AdCre virus to infect various brain 
regions including the cerebellum in adult mice, however in newborn mice, it is 
impossible to tell from this study which cell types were infected. This virus is driven 
by the herpes simplex virus thymidine kinase gene enhancer/promoter, however, our 
AdCre uses the MCMV gene promoter. This murine CMV was shown to be 5-30% 
more efficient than the human CMV promoter (in luciferase assays), which is 
commonly used in Ad vectors (Addison et al. 1997). This study by Addison et al. 
(1997) however did not directly inject adenovirus into the brain, instead the in vivo 
part of their study only included intratumoral injection. The rest of their study was 
conducted in vitro. Adenoviruses are know to infect some tissues and cell types less 
efficiently (Badorf et al. 2002), however, we could not have known that our AdCre 
upon injection into our early postnatal mice would only infect cells of the choroid 
plexus. In retrospect, it may have been better to try to obtain our AdCre directly from 
Y. Wang’s group as their AdCre has been shown to work, however time constraints 
made it necessary to obtain our AdCre from a commercial source. It is also of note 
that Microbix’s AdCreM2 virus has not yet been described in the literature at the time 
of writing.  
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A technical difficulty which could have contributed to the poor infection rate by the 
AdCre virus was that when performing the injections, the needle should inserted into 
the brain, and held still after infection of the adenovirus for as long as possible to 
allow the viral solution to dissipate, before the needle is removed as slowly as 
possible. The difficulty was that some viral solution was often drawn out when the 
needle was removed. A solution to this would be to leave the needle in for longer, 
however, it is also very important that the mice should not be left chilled for too long, 
otherwise they would die. However, this is unlikely to be the only reason that 
cerebellar cells were not infected with AdCre since choroid plexus cells were 
consistently the only cells infected in each of the brains tested.  
 
To gain a more definitive answer to Apc’s role in medulloblastoma, we one could use 
a different mouse line to mutate Apc in the cerebellum postnatally. Two possibilities 
would be to use a Nestin-CreER mouse such as the one which has recently been 
produced by Imayoshi et al. (2006). In this mouse, CreER, a fusion of Cre and the 
mutated ligand-binding domain of the human oestrogen receptor α, is inactive for 
recombination but becomes activated by administration of tamoxifen (Feil et al. 
1997). Expression of CreER is driven by the Nestin promoter and enhancer (Imayoshi 
et al. 2006). We could cross this Nes-CreER strain to our floxed Apc mice and then 
administer tamoxifen to mice at P4 stage of development. Another option would be to 
use a Math1-CreER (Machold and Fishell 2005). Similar to Nestin, Math1 is 
expressed strongly in the cerebellum at postnatal day 4 of mouse development 
(Machold and Fishell 2005). Using one of these mouse strains, we would carry out the 
experiment as follows. Firstly, we would cross the cre strain of mouse (eg Nes-
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CreER) to the reporter strain R26R. We would then administer tamoxifen and remove 
the brains for histological analysis. This experiment would indicate whether we are 
targeting the correct populations of cells efficiently. We would then produce Nes-
CreER+;ApcLoxP/LoxP mice and administer tamoxifen to at least 100 animals at P4 of 
development. 10 animals would then be sacrificed at certain time intervals (eg every 7 
days up until 8 weeks post tamoxifen administration). Mice would be examined 
histologically with haematoxylin and eosin staining, as well as 
immunohistochemically with Apc and β-catenin staining to look for tumour formation 
and whether or not Apc has been efficiently mutated and whether the Wnt pathway 




5. Apc’s role at the midbrain hindbrain junction 




Medulloblastoma is a tumour which predominantly manifests in childhood. As 
discussed in Chapter 1, MBs are thought to have neurodevelopmental roots, so 
understanding the role of Apc in normal cerebellar development would shed light on 
its possible role in MB. 
  
To study Apc’s role in cerebellar development, we used our conditional allele of Apc 
to assess the consequences of losing Apc in a cell population that gives rise to the 
cerebellum: the midbrain-hindbrain junction. To do this we obtained a line of 
transgenic mice which expresses cre recombinase under the Engrailed-1 promoter 
(En1-cre mice) (Gifted from Wolfgang Wurst, Institute of Developmental Genetics, 
Munich). Engrailed (En) is a homologue of the Drosophila engrailed (en) gene. 
Expression of En1 begins in the mouse at the 1-somite stage in the anterior 
neuroepithelium (Davidson et al. 1988).  Later, expression can be seen more ventrally 
in band of cells whose population gives rise to the mid-hindbrain region. By E9.5, 
En1 expression can be seen in a rostral to caudal progression in two lateral stripes 
along the hindbrain and spinal cord. By this stage, expression can also be observed in 
the somites and the ventral extoderm of the limb buds. In the adult mouse brain, En1 
is expressed in groups of motor nuclei in the pons and the substantia nigra (Wurst et 
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al. 1994). A fate-mapping study by Zinyk et al. (1998) which utilised an En2-cre 
strain of mouse crossed to a reporter strain which consists of a loxP – stop of 
transcription/translation – loxP – lacZ, showed that tissues derived from the midbrain-
hindbrain region during embryonic days 9 – 12, contributed significantly to the 
medial cerebellum and colliculi (Zinyk et al. 1998).  
En1 is a transcription factor involved early in development, establishing the body plan 
and in particular, for defining the posterior half of each parasegment (Kornberg 1981). 
Of note, En1 is also a known target of Wnt signalling (Danielian & McMahon 1996). 
Later it determines neuronal identity of, for example, midline serotonergic neurones 
in drosophila (Lundell et al. 1996). En1 in the mouse is known to play an important 
role in embryonic development of the brain and limbs (Joyner 1996; Loomis et al. 
1998).  During early neural development in the mouse, En1 is thought to be critical 
for the development and patterning of the mid and hindbrain region (Araki & 
Nakamura 1999; Wurst et al. 1994).  
En1-/- mice have a deletion in the dorsal and ventral parts of the midbrain and rostral 
hindbrain (Wurst et al. 1994). In contrast, En2-/- mutant mice show only subtle 
cerebellar defects (Millen et al. 1994). When combined, mice with an En1-/-;En2-/- 
double mutation show a complete deletion of mid-hindbrain region indicating that the 
En genes are involved in the maintenance of a functional mid-hindbrain organiser 
(MHO).  
Since En1 is expressed at the boundary between the embryonic mid- and hindbrain, an 
area that gives rise to the future anterior part of the cerebellum, creating a line of mice 
where Apc is mutated in En1 expressing cells should indicate Apc’s role in early 
cerebellar development. A study by Panhuysen et al. (2004), examining the role of 
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Wnt1 in the developing mid-hindbrain region, ectopically expressed Wnt1 under the 
control of the endogenous En1 promoter. This approach extended Wnt1 expression 
rostrally into the anterior midbrain and caudally into rhombomere 1, causing 
overproliferation of precursor cells in the caudal midbrain in a gene dosage dependent 
manner. The authors of this study suggested that Wnt1 primarily acts as a regulator of 
proliferation of specific precursor populations in the developing mid-hindbrain region, 
and is secondarily involved in maintenance of the MHO (Panhuysen et al. 2004). This 
study backed up previous studies using a Wnt1 null mutant mouse have shown an 
absence of midbrain and cerebellar structures (McMahon & Bradley 1990), and 
increased cell death in the metencephalon (Serbedzija et al. 1996), implying that Wnt1 
is necessary for development of the midbrain and cerebellum.  
By generating En1cre+;ApcLoxP/LoxP mice, we hope to examine Apc’s role in midbrain 
and early cerebellar development. As discussed in chapter 1, the main consequence of 
the loss of Apc is functionally equivalent to constitutive activation of canonical Wnt 
signalling, leading to the stabilisation of β-catenin and its translocation to the nucleus. 
Of note, the En1cre mice are knock-in mice where the cre-recombinase gene cassette 
has been knocked into the En1 locus (Kimmel et al. 2000). This produces a null 
mutation in En1, therefore all of our En1cre mice are heterozygous. 
Since Wnt signalling is critical for normal development of the mid-hindbrain region, 
we hypothesised that our En1cre+;ApcLoxP/LoxP mice would have major abnormalities 
in the midbrain and the anterior cerebellum. In particular we expected a phenotype 
similar to the one seen by Panhuysen et al. (2004) in their mutant as overexpressing 
Wnt1 should have the same effect as reducing Apc levels. However, we did not expect 
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that the phenotype would be identical due to Apc’s roles outside the Wnt pathway, 




5.2.1 Validation of the En1-cre mouse strain 
To ensure that our En1-cre mice were expressing cre-recombinase efficiently and in 
the expected pattern, we crossed it to a ROSA-26 reporter (R26R) strain which 
expresses β-galactosidase in the presence of cre-recombinase (Soriano 1999). These 
R26R mice have a loxP-flanked stop cassette followed by lacZ gene in the ROSA-26 
locus (Soriano 1999). The resultant progeny were collected at embryonic days 16 and 
18, and stained with X-gal to reveal β-galactosidase expression. As shown in Figures 
5.1 and 5.2, cre-recombinase was expressed efficiently in the midbrain and the 
hindbrain following what appears to be the normal expression pattern of En1 (Davis 
& Joyner 1988; McMahon et al. 1992), with staining in the hindbrain as well as in all 
but the dorsal layers of the midbrain and cerebellum. This staining was performed on 
whole mount embryos however, so the cellular resolution is not very high. In 
conclusion, we believe that the expression pattern of cre looks very close to what we 
would expect of the expression pattern of En1.  
 





5.2.1 Phenotype of En1cre+;ApcLoxP/LoxP embryos 
To begin our study of this mutant mouse, embryos were collected at various stages of 
development and sectioned sagittally before bein stained with haematoxylin and 
eosin. The embryos’ morphology were then carefully examined. En1cre+;ApcLoxP/LoxP 
mice at the early developmental stage of E10.5 were discovered to have a relatively 
subtle phenotype. No obvious abnormalities were noted at low magnification, 
however upon closer inspection, cells along the ventricular zone of the developing 
midbrain had a disorganised structure with occasional rosette-like formations, which 
were absent in the control En1cre+;ApcLoxP/LoxP littermates (Figure 5.3A-D). We 
looked this early in development for any abnormalities even though the cerebellum 
has not started to form (and doesn’t become apparent until around E15.5), because we 
wanted to try to identify when the mutation first became apparent, and how severe it 
is at this very early stage.  
 
At E12.5, one of the En1cre+;ApcLoxP/LoxP mice appears to have enlarged 
mesencephalic, 3rd and 4th ventricles, which indicates that the mouse is suffering 
from hydrocephalus (Figure 5.4B). Also of note was a cluster of disorganised cells at 
the junction between the midbrain and hindbrain (Figure 5.4C) which is absent from 
control En1cre-;ApcLoxP/LoxP mice (Figure 5.4A).  In keeping with this phenotype, 
another En1cre+;ApcLoxP/LoxP embryo taken at E12.5 displayed enlargement of all 
vesicles with the exception of the lateral ventricle (Figure 5.4D). This embryo differs 
from the previous however in that it displays at much larger area of disorganised 
tissue in the caudal midbrain / mid-hindbrain junction (Figure 5.4E).  
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A third E12.5 En1cre+;ApcLoxP/LoxP mutant embryo showed another differing 
phenotype. Hydrocephalus was not as pronounced although the lateral ventricle may 
be slightly enlarged, however, the most striking phenotype is a very large area of 
disorganised cells in the midbrain (Figures 5.4F-G). As much care as possible was 
taken to match these sections although there may be variation due to differences 
across medio-lateral tissue or variability across embryos. As a rough marker, the size 
of the telencephalon and size of the lateral ventricle were used to match sections 
although the latter is not so accurate due to variations in hydrocephalus between 
animals.  
In wild-type mice at E15.5, the ventricles are reduced in size and (as discussed in 
Chapter 1) the cerebellum should be evident (Figure 5.5A). However, when 
comparing our En1cre+;ApcLoxP/LoxP mice to the control En1cre+;ApcLoxP/LoxP 
littermate, one can see that all ventricles are greatly enlarged in both embryos, 
indicating hydrocephalus. Also, the cerebellums appear under-developed with an 
arrowhead in Figures 5.5C and E, indicating the location of the presumptive 
cerebellums. 
Once we had established that there was a phenotype in the En1cre+;ApcLoxP/LoxP mice, 
we expanded our evaluation of the mutants by performing immunohistochemial 
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5.2.2 Characterisation of Apc expression in conditional mutant 
embryos.  
We used an anti-Apc antibody (Santa Cruz) that recognises a C-terminal epitope that 
is absent in the mutated form of Apc due to the frame-shift mutation caused by the 
deletion of exon 14. Therefore, performing immunohistochemistry with this antibody 
should accurately indicate where Apc has been deleted.  
 
At E16.5, En1cre+;ApcLoxP/LoxP mutant mice show severe hydrocephalus with an 
enlargement of all ventricles of the brain. In addition to this, mutant mice display an 
area of abnormal tissue at the mid-hindbrain junction. Apc is expressed strongly 
throughout the entire CNS at E17.5 including the mid-hindbrain area (Bhat et al 1994) 
(Figure 5.6A). Although, the exact cell types which express Apc is still controversial. 
However, mid-hindbrain junction in En1cre+;ApcLoxP/LoxP mutant mice is now 
populated with cells which appear to be mesenchymal cells (Figure 5.6B-E). We 
performed Apc immunohistochemistry and found that these cells do not express Apc 
protein. Usually situated ventrally to these mesenchymal cells, is an area of 
disorganised neuroblastic cells, which are also negative for Apc expression  (Figure 
5.6D-E).  
 
Cells in this area seem to be arranged in a turbulent fashion with small clusters of 
cells interspersed with other unidentified cell types. The only En1cre+;ApcLoxP/LoxP 
mutant embryo, out of a total of 27, to not display this tumour-like ball of 
disorganised cells is displayed in Figure 5.6B.  
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5.2.3 Expression of β-catenin in conditional mutant embryos 
To further characterise this area of dysregulated tissue, we carried out β-catenin 
immunohistochemistry on En1cre+;ApcLoxP/LoxP mutants at a range of developmental 
stages from E13.5 to E18.5. In control En1cre-;ApcLoxP/LoxP mice, β-catenin is 
expressed strongly throughout the brain (Figure 5.7A). However, situated at the mid-
hindbrain junction of mutant En1cre+;ApcLoxP/LoxP mice, we can see a large β-catenin 
negative area (Figure 5.7E, marked with an asterisk). The cells of this area appear, 
based on morphology, to be mesenchyme cells which have invaded ventrally into the 
brain. They express β-catenin at very low levels with some cells showing nuclear 
localisation (Figure 5.8B). This tissue normally displays β-catenin in some nuclei, and 
has also been shown not to express Apc in our En1cre-;ApcLoxP/LoxP control mice 
(Figure 5.7A). In the disorganised mass of neuroblastic cells located ventrally to the 
mesenchyme cells, nuclear β-catenin staining can be observed indicating that there is 
loss of functional Apc in these cells (Figures 5.7F, and 5.8D), which has effectively 
activated the Wnt signalling pathway. Of note, not all cells in this dysregulated area 
express β-catenin, suggesting that there are at least two types of cells in this area. 
Also, Homer-Wright rosettes, which are common in human MBs and signify neuronal 
differentiation (Prof. Ian Whittle, Pers Comm), can be observed in this dysregulated 






5.2.4 Pax3 expression in conditional mutant embryos 
In addition to examining the disorganised area at the mid-hindbrain region, we were 
interested in examining the effect that mutating Apc in the midbrain and rostral 
hindbrain had on the development of these areas.  
We used an anti-Pax3 antibody which is expressed strongly in the midbrain and EGL 
of the developing cerebellum to look for possible changes in cell fate. In the area of 
disorganised tissue, Pax3 expression can be observed in a large proportion of cells 
(Figure 5.9 B and D). When comparing mutant mice to controls at E13.5 and E15.5, it 
can be seen that there is still Pax3 staining where we would expect it in the ventricular 
zone of the midbrain and in the EGL of the CB. This suggests that the midbrain 
region has not been deleted by mutating Apc in this area. Similarly with the 
cerebellum, this structure does not seem to be significantly reduced or enlarged in size 
compared to controls. The histological differences between control mice and mutant 
mice seem to stem from the effect of hydrocephalus and not due to loss of Apc 
deleting or expanding mid- or hindbrain structures. Of note, a proportion of cells 
contained within the disorganised neuroblastic mass express Pax3. 
We let a total of seven litters go to full term. The resulting litters were small (with an 
average size of five pups), and none of the pups had the desired En1cre+;ApcLoxP/LoxP 
genotype. The null hypothesis would state that the resultant progeny were expected to 
follow Mendelian genetics giving us 1 out of 4 animals of the mutant 
En1cre+;ApcLoxP/LoxP genotype. To test this hypothesis, a chi-squared test was 
performed to compare the observed results against the expected result. The result of 
this test showed p< 0.001, hence we can reject the null hypothesis that the observed 
values of our cross are the same as the theoretical distribution of a 3:1 ratio. To recap, 
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mice survived to at least E18.5, but as no En1cre+;ApcLoxP/LoxP mutants were found 
after birth, and taking in to account the severity of the brain abnormalities, we believe 





This set of experiments was set up to assess Apc’s role in midbrain and early 
cerebellar development. The reasoning was as follows: Medulloblastoma is thought to 
stem from dividing neural precursor cells of the outer layer of the cerebellum (Kadin 
et al. 1970; Marino et al. 2000; Reddy & Packer 1999). A proportion of MBs have 
lost Apc or otherwise show evidence of dysregulated Wnt siganlling and Wnt 
signalling is known to be important for the normal development of the cerebellum 
(McMahon & Bradley 1990). We therefore chose to attempt to address the role of 
Apc in the early development of the midbrain-hindbrain region in the expectation that 
it might shed light on the developmental origins of medulloblastoma. 
As discussed earlier in this chapter, Panhuysen et al. (2004) ectopically expressed 
Wnt1 under the control of the En1 promoter. We expected that our 
En1cre+;ApcLoxP/LoxP mutant mouse would display a similar phenotype as the 
Panhuysen En1+/Wnt1 knock-in mutant as the effect of overexpressing Wnt1 has a 
similar result to deleting Apc by increasing cytoplasmic β-catenin which can in-turn 
translocate to the nucleus and turn on downstream targets of the Wnt pathway such as 
c-myc and cyclinD1. The En1+/Wnt1 mutant displays an enlarged inferior colliculus 
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(IC), which is a structure located in the dorso-caudal midbrain. En1+/Wnt1 mice are 
viable and fertile, while En1Wnt1/Wnt1 mice die at P0 and exhibit an even larger IC 
(Panhuysen et al. 2004).  It is thought that En1Wnt1/Wnt1 mice display an exaggerated 
phenotype not only due to having additional copies of Wnt1, but also as a 
consequence of completely losing En1 expression (Panhuysen et al. 2004). Of 
interest, the phenotype of the En1Wnt1/Wnt1 mouse differs from the previously published 
work from the same laboratory which created an En1-/- mutant mouse that lacked 
midbrain and hindbrain structures (Wurst et al. 1994). That implies that the difference 
in phenotype seen between the En1+/Wnt1 and the En1Wnt1/Wnt1 mice is not just 
attributable to loosing En1 function in the mid-hindbrain, instead it is probably due to 
both the loss of En1 function and the overexpression of Wnt1.  
In our mutant mice, we saw mesenchyme tissue invading ventrally into the CNS at 
E13.5 of development. Closely associated with this mesenchyme tissue is a mass of 
neuroblastic cells which are negative for Apc staining, but do display nuclear β-
catenin and Pax3 staining. There are a few possibilities to account for this phenotype. 
Firstly, it is difficult to know if the neuroblast tissue is giving abnormal signals to 
make the mesenchyme grow into neural tissue or whether the mesenchyme is causing 
the abnormal blast tissue to form. Another explanation could be that the loss of Apc in 
the mid-hindbrain region is causing cells to die, thus creating a space for adjacent 
tissue to grow into. Indeed, a study by Hasegawa et al. (2002) showed a similar result 
when they conditionally mutated Apc in neural crest cells which resulted in massive 
apoptosis of cephalic and cardiac neural crest cells from E11.5 of development 
through to birth.   
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I believe that the hypothesis that loss of Apc caused large amounts of cell death 
leading to surrounding tissue invading the space is unlikely however, because of 
previous studies suggest that overexpressing Wnt1 under the control of the En1 
promoter (En1+/Wnt1) increases cell proliferation in the dorsal midbrain (Panhuysen et 
al. 2004). Further, if Wnt1 controls cell proliferation in the early development of the 
midbrain, it must play a role in its maintenance. Maintenance of the midbrain is in 
turn necessary to sustain the MHO and subsequently the entire mid-hindbrain region 
(Panhuysen et al. 2004). To reinforce this, experiments that created Wnt1-null 
mutants, show a deletion of the entire mid-hindbrain region including the MHO at 
early stages of gestation (E8.5) (McMahon & Bradley 1990; McMahon et al. 1992; 
Thomas & Capecchi 1990).  In addition to these studies on the effects of Wnt1 in the 
developing brain, the study by Chen & Walsh (2002) showed that ectopic expression 
of β-catenin in the brain results in enhanced proliferation of neuronal progenitor cells. 
This ties in with the theory that canonical Wnt signalling enhances growth of neuronal 
precursor cells (Chenn & Walsh 2002). 
I believe most likely explanation is that the loss of Apc causes the disorganised 
tumour-like region of cells and in these cells, β-catenin is translocated to the nucleus 
and activates Wnt target genes such as CyclinD1 and matrix metalloproteinase MT1-
MMP which are known to stimulate human mesenchymal stem cell (hMSC) 
proliferation by 40% (Neth et al. 2006). In a study by Neth et al. (2006), hMSCs were 
stimulated with recombinant Wnt3a and conversely had β-catenin expression 
knocked-down using RNA interference technology. The results of this study showed 
that stimulation of hMSCs with recombinant Wnt3a increased by 2-fold their ability 
to migrate and invade surrounding tissues. Using the reverse approach, by knocking 
down β-catenin expression (and hence down-regulating cyclinD1 and MT1-MMP), 
126 
reduced hMSC proliferation rate and invasion capacity by 64% and 52% respectively 
(Neth et al. 2006). This study lends weight to the hypothesis that the Apc-negative 
mass of cells in the mid-hindbrain region is stimulating the mesenchyme tissue to 
proliferate and invade the neural tissue.  
Of note also is that this tumour-like cell cluster ectopically expresses Pax3. This 
transcription factor and the Pax3 fusion protein PAX3-FKHR (which contains the 
DNA binding domain of Pax3 and the potent transcriptional activation domain of 
FKHR), have been implicated in cell transformation and tumourgenesis. Indeed, 
aberrant Pax3 expression is often found in various tumour types such as melanoma, 
rhabdomyosarcoma, neuroblastoma and small cell lung cancer (Muratovska et al. 
2003; Parker et al. 2004). 
The other major phenotype found in all of our En1cre+;ApcLoxP/LoxP mutant mice is 
hydrocephaly.  Hydrocephaly can be defined as a brain pathology characterized by 
increased volume of CSF associated with enlargement of the head, and progressive 
brain atrophy (Forni et al. 2006).  CSF is an important determinant of the extracellular 
fluid that bathes neurons and glia in the CNS. The choroid plexus maintains the 
chemical stability of the CSF, and not only continuously produces CSF, but it also is 
responsible for active transport of metabolites out of the CNS and into the blood. The 
rest of the CSF which is not secreted by the choroid plexus, is secreted by capillaries 
in the brain. There are a few factors that could cause an animal to become 
hydrocephalic. These include, loss of brain tissue causing ventricles to expand, 
impaired absorption of CSF, or an obstruction in the exit foramina or arachniod villi. 
Oversecretion of CSF is rare but is thought to occur in some functioning tumours of 
the choroid plexus (papillomas) (Kandel et al 1996). Although subarachnoid 
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hemorrhage and high CSF protein content also characterize these tumours which 
could lead to impaired reabsorption of CSF (Kandel et al 1996). Obstruction of CSF 
pathways could result from tumours, congenital malformation, or scarring. Lastly, 
impaired abdorption of CSF could conceivably result from any condition that raises 
the venous pressure, such as thrombosis or severe congestive heart failure (Kandel et 
al 1996).  
In some En1cre+;ApcLoxP/LoxP mutant embryos there appears to be a loss of hindbrain 
tissue (shown in Figures 5.8C and E). This loss of tissue could explain an enlargement 
of the 4th ventricle, however all ventricles are enlarged so this explanation cannot be 
the main cause of hydrocephalus in these embryos. A more likely explanation is that 
there is either some form of obstruction, possibly caused by the drainage mechanisms 
failing to develop properly, or that an excess of CSF is being produced. As far as I am 
aware, there have been no published studies linking Apc or Wnt signalling with the 
development of drainage mechanisms such as the exit foramina or the arachnoid villi. 
There is also no mention in the literature of a role for Wnt signalling in CSF 
production. The results of this study is reminiscent of the AdCre infected animals, 
some of which also developed hydrocephalus, indicating that Apc may be involved in 
regulating fluid balance in the choroid plexus.  
As mentioned above, the dorsal midbrain still develops although the phenotype varies 
between En1cre+;ApcLoxP/LoxP mutants. In some the dorsal midbrain appears shorter 
and thicker (Figures 5.5B, 5.9B) and in others the dorsal midbrain appears elongated 
and thin (Figures 5.5 D, 5.9D). These variations in the dorsal midbrain are most likely 
a secondary consequence of hydrocephalus otherwise we would expect to see a more 
consistent phenotype. There is one area of the brain where we have consistently 
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observed a loss of tissue, and that is the rostroventral hindbrain region (Figures 5.8C 
and E illustrate this).  This area of the hindbrain contains the medulla oblongata which 
controls heart and lung functions.  
Given more time, it would have been an interesting side experiment to look at the 
limbs of our En1cre+;ApcLoxP/LoxP mutants. It is known that Wnt signalling plays a role 
in limb development at the AER in the chick. During development of the limb, Fgf8 
and Fgf10 are known to play a key role in the control of limb initiation and in the 
induction of the AER (reviewed by (Cohn & Tickle 1996). A study by (Kawakami et 
al. 2001) conducted in chick embryos, showed that several Wnts (Wnt2b, Wnt3a and 
Wnt8c), acting through β-catenin, are as key regulators of Fgf8 and Fgf10. Ectopically 
expressed Wnt2b and Wnt8c, acting through Fgf10 were able to induce ectopic limbs 
in the embryonic flanks. They also show that the induction of Fgf8 in the limb 
ectoderm by Fgf10 is mediated by the induction of Wnt3a  (Kawakami et al. 2001).  
Given the important role that Wnts play in the development of chick limbs, a possible 
result of loss of Apc in the AER could be an overgrowth of the limbs, a process 
mediated through Fgf8 and Fgf10.  
Other future experiments could try to address in more detail the effect of loss of Apc 
in the mid-hindbrain. Markers of this region such as Fgf8, Pax2, En1, En2, Otx2 and 
Gbx2 would allow us to assess more fully the phenotype (ie a shift in Otx2 and Gbx2 
expression would indicate a shift in the MHO, or the loss of a regional marker would 
imply that the region in question had been lost). Studying the expression patterns of 
these genes would also shed more light on the interactions between them and the Wnt 
pathway. 
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The area of hindbrain which contained the medulla oblongata appears to have been 
lost or reduced in size in En1cre+;ApcLoxP/LoxP mutants. A stereological analysis of the 
midbrain and hindbrain would more accurately tell us how much tissue has been lost. 
This would also definitively tell us whether the phenotype is due to tissue failing to 
develop, or cells in this area dying, or whether intercranial pressure caused by 
hydrocephalus is compressing this area making it appear smaller in size. If cells are 
being lost in this area, it could be due to either cell death, or a failure of cells to form 
in the first place. TUNEL (Terminal Deoxynucleotidyltransferase-Mediated dUTP 
Nick End Labeling) staining is a method for studying apoptosis in cell populations 
and would give us an indication on the levels of cell death in the hindbrain. An 
abnormally high level would indicate that cells in this area are dying as a result of 
losing Apc in the midbrain and anterior hindbrain.  
We could also study proliferation levels in the mid-hindbrain region of 
En1cre+;ApcLoxP/LoxP mutants using a BrdU approach. This will label cells which are 
undergoing s-phase in the cell cycle. It would be interesting to see whether cells 
within the tumour-like disorganised area of cells at the mid-hindbrain border area 
proliferating or whether they are differentiated. If this area is behaving as a malignant 
tumour, we would expect the cells to be actively dividing. Given that a large 
proportion of cells in this area show nuclear β-catenin localisation, and that an active 
Wnt signalling pathway often leads to increased proliferation, I would expect that 
these cells were dividing aggressively. Also, it appears that these tumour-like cells 
could be associated with the mesenchyme tissue, especially since there is 
mesenchyme tissue located inside the mass of disorganised cells. Tumours such as 
gliomas (McComb & Bigner 1985), as well as well as glioblastomas (Tso et al. 2006) 
have been shown to express mesenchyme immunhistochemical markers. Indeed, a 
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study by Tso et al. (2006) showed that genes associated with mesenchymal tissue but 
not to neural lineage such as TKL-40, TNC, osteonectin, and CD105 were 
overexpressed in glioblastomas suggesting that these tumours possess mesenchymal 
properties (Tso et al. 2006). It would be very interesting to test these tumour-like cells 
for these mesenchymal marker genes by in situ hybridisation or test for 
overexpression of the proteins by immunohistochemistry. If these proteins were 
overexpressed, then it might suggest that this area had similar characteristics to those 
of glioblastomas. 
This study is not the only one to make use of the ApcLoxP mouse. This mouse was 
originally created by Shibata et al. (1997) who produced the Apc580s mouse (as it was 
originally named) to study the effects of conditionally mutating Apc in the intestine. It 
is of note, that the ApcLoxP mouse is a hypomorphic mouse, meaning that it has less 
than normal expression levels of the wild type Apc gene. This is thought to be a 
consequence of leaving the neo cassette in the intron when creating the mouse.  
There have however been many studies utilising this mouse and mutating Apc in 
various tissues with severe phenotypic effects. For example, as mentioned earlier, 
Sansom et al. (2004) used this mouse to mutate Apc the gut epithelium. The resulting 
mutant cells displayed abnormal apoptosis, differentiation, migration and proliferation 
resulting in Apc mutant cells reverting to stem cells and ultimately leading to multiple 
colorectal adenomcarcinoma formation (Sansom et al. 2004). 
Another study used the ApcLoxP mouse in conjunction with an AdCre vector to mutate 
Apc in the liver. The resulting mice showed a marked phenotype with greatly 
enlarged hepatocytes and rapid mortality (Colnot et al. 2004). When the adenovirus 
was administered at a lower dose, 67% of mice developed hepatocellular carcinoma 
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(HCC), implying that this mouse makes a very good model for studying cancer in the 
liver. 
In the prostate, mutating Apc results in hyperplasia after 4.5 weeks of age and 
adenocacrinoma after 7 months (Bruxvoort et al. 2007), again implying that Apc is a 
potent tumour suppressor.  
Gallagher et al. (2002) looked at the effects of mutating Apc specifically in the 
mammary gland to assess Apc’s role in breast tumours. Mutant mice showed a 
marked delay in mammary duct network growth and during lactation, mice developed 
multiple metaplastic growths, although these did not progress to neoplasia. It was only 
when Tcf-1 was also mutated in these mice, that acanthoma’s, a tumour of the 
epidermis, formed.  
As mentioned earlier, a study carried out by Hasegawa et al. (2002), looked at the 
effects of loss of Apc in the neural crest, leading to severe apoptosis of cardiac and 
neural crest cells, however there was no sign of tumour formation.  
These investigations all point towards the conclusion that conditionally mutating Apc 
in various tissues leads to severe mutations and usually death. It is interesting that not 
all mutations lead to the same outcome. For instance, deleting Apc in the gut leads to 
formation of multiple adenomas, whereas deleting Apc in the prostate leads to growth 
of a tumour which does not metastasise, and in the breast metaplastic growths form 
but do not progress to neoplasia. This is could due to regional variation in the function 
of Apc and also the effects of other signalling factors. The differences in phenotypes 
could also be due to different potencies of the cre-recombinase used. For instance in 
Sansom et al.’s (2004) paper, when they reduced the concentration of cre 
administered, the phenotype reduced in severity. 
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6. FINAL DISCUSSION 
 
The main aim of this project was to assess the role of Apc in medulloblastoma. Our 
central hypothesis was that by specifically mutating Apc in the hindbrain of early 
postnatal mice, we could produce a mouse model of medulloblastoma. We took three 
approaches to this. Firstly, we attemped to specifically inactivate Apc in neural 
precursor cells in the early postnatal hindbrain using the cre-loxP system. We then, 
inactivated Apc during embryonic development of the cerebellum, again using cre-
loxP tissue-specific gene targeting. This experiment aimed to assess Apc’s role in 
early development of the midbrain and hindbrain and the hypothesised that our 
En1cre+;ApcLoxP/LoxP mice would have major abnormalities in the midbrain and the 
anterior cerebellum. In particular we expected a phenotype similar to the one seen by 
Panhuysen et al. (2004) in their mutant as overexpressing Wnt1 should have the same 
effect as reducing Apc levels. 
 
We sought to produce a mouse model of MB by mutating Apc in the early postnatal 
hindbrain of mice by firstly using the RCAS/tv-a system, and then when that proved 
unsuccessful, we used the AdCre method. From this we hoped to learn whether the 
loss of Apc in the hindbrain could lead to MB formation. However, as we were unable 
to successfully mutate Apc in the granule-cell precursor cells of the cerebellum, we 
could not produce a suitable mouse model of MB and determine Apc’s role in the 
development of MB in mice. However, we could take these experiments further by 
using a different mouse line to mutate Apc in the cerebellum postnatally. Two 
possibilities would be to use a Nestin-CreER mouse or the Math1-CreER mouse 
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(Machold and Fishell 2005). The experiments would be carried out as described in 
section 4.3. 
 
The final part of this project involved using the En1cre mouse and crossing it to the 
ApcLoxP/LoxP strain to examine Apc’s role in midbrain and early cerebellar 
development. As discussed earlier, MB is thought of arise from granule cell precursor 
cells and by an alteration of the normal developmental pathway causing unrestrained 
cellular growth. Therefore, examining the loss of Apc at the mid-hindbrain junction 
could shed light on how MBs develop. The resulting En1cre+;ApcLoxP/LoxP mutants 
showed an unexpected and exciting phenotype by displaying hydrocephalus in all 
ventricles and an in-growth of mesenchyme tissue at the mid-hindbrain border, 
closely associated with a tumour-like area of cells showing activated Wnt signalling. 
This mutation was found to be embryonically lethal. Time restrictions limited the 
current study of this mutant, so future work could again look more closely at the 
choroid plexus in these mutants and try to assess the role Apc in this structure is 
playing on the hydrocephalic phenotype found in all En1cre+;ApcLoxP/LoxP mice. The 
histology of the choroid plexus could be looked at in more detail, comparing WT 
mice with En1cre+;ApcLoxP/LoxP mutant mice. If this structure was found to be 
histologically altered in mutant mice, then perhaps the hydrocephaly is being caused 
by an overproduction of CSF by the choroid plexus. Alternatively drainage structures 
such as the exit foramen could be studied histologically. If these were found to be 
blocked, or if they have not formed in the first place, then one could argue that 
hydrocephaly is being caused by an inability of CSF to drain from the ventricles. 
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Expression patterns of genes of the mid- and hindbrain such as Fgf8, Pax2, En1, En2, 
cyclinD1, Otx2 and Gbx2 could also be studied, which would give more insight into 
whether or not structures have been lost or shifted in the midbrain and hindbrain 
regions. For instance, it might shed light on whether structures such as the mid-
hindbrain junction have moved because of the effects of hydrocephalus. Also, testing 
these markers on the tumour-like area of cells at the mid-hindbrain junction might 
give us more information on the cells in this area. For example, cyclinD1 is a key 
regulator of G1 to S phase progression in the cell cycle, and promotes proliferation 
(Shtutman et al. 1999) so if it is highly expressed in this tumour-like area, then it 
might lend weight to the theory that a loss of Apc could lead to increased β-catenin 
levels may thus promote neoplastic conversion by triggering cyclinD1 gene 
expression and, consequently, uncontrolled progression into the cell cycle. Taking this 
further, examining this area with a BrdU (bromodeoxyuridine) and IddU 
(iododeoxyuridine) double labelling approach would give us an accurate measure of 
their cell cycle kinetics. This would tell us how quickly these cells are dividing and 
give an insight into whether the cells are differentiating or not. Also, 
immunohistochemistry for proteins such as cyclinD1 and MT1-MMP could give 
insight on whether this tumour-like area of cells is cauing mesenchyme tissue to 
invade ventrally into the midbrain.   
 
Further, a stereological analysis of the hindbrain could definitively tell us whether the 
apparent loss of tissue in this area is due to a loss of cells or an effect of pressure 
caused by hydrocephalus, compressing the area. TUNEL staining could also be used 




In a study not related to the brain, it would be interesting to look at the limbs of our 
En1cre+;ApcLoxP/LoxP mutants as is known that Wnt signalling plays a role in limb 
development at the AER in the chick (Cohn & Tickle 1996). It is very likely that the 
limbs of these mice are mutated and characterising this mutation would be a novel 
study.  
 
In conclusion, I believe that components of the Wnt pathway such as Apc play an 
important role in the development of some MBs. This can be seen through Turcots 
patients with mutations in Apc displaying MBs, as well as studies such as ours who 
have tested MBs for mutations of components of the Wnt signalling pathway such as 
β-catenin, Apc and axin and found mutations of proteins in the Wnt pathway occur in 
around 15% of sporadic MBs (Baeza et al. 2003; Eberhart et al. 2000; Huang et al. 
2000; Koch et al. 2001). It is also clear however, that other signalling pathways play 
at least an equal role in MB development. For instance many studies have looked at 
the role of Hedgehog signalling in MB, and shown that around 30% of sporadic MB 
carry mutations in components of the Shh pathway such as PTCH1, SUFU and SMOH 
(Pietsch 1997; Raffel et al. 1997; Reifenberger et al. 1998; Taylor et al. 2002; Xie et 
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8.1 Solutions and Reagents 
 
 
Ampicillin (Amp)  
0.5g  Ampicillin (Sigma A-9518) 
dH2O to 100ml, filter-sterilise and store at -20°C (100µg/ml working concentration) 
 
Buffer QBT (Equilibration buffer) 
750mM  NaCl 
50mM  MOPS (pH 7.0) 
15%  isopropanol 
0.15%   Triton® X-100. 
 
Buffer QC (wash buffer) 
1.0M   NaCl 
50mM  MOPS (pH 7.0) 
15%   isopropanol. 
 
Buffer QF (Elution buffer) 
1.25M  NaCl 
50mM  Tris (pH 8.5) 
15%   isopropanol 
 
Church Hybridisation Buffer 
5g   BSA (Bovine Serum Albumin)  
Dissolve in 75 ml of water, then add 
250ml   1M Na2HPO4  (pH 7.2) 
175ml   20% SDS 
1ml   0.5M EDTA  
  
Church Wash    
40ml  1M Na2HPO4  (pH 7.2) 
50ml   20% SDS 
2ml   0.5M EDTA  
 
DNase-free RNase A 
200mg  RNase A (Sigma R-5500) 
3.3µl  3M NaOAc, pH 4.5 
dH2O to 10ml 
boil for 10minutes (aliquot and store at –20°C) 
 
0.5 M EDTA, pH 8.0 (disodium ethylenediamine tetraacetate)  
186.1g  Na2EDTA 
Dissolve in approx. 400ml dH2O, adjust pH to 8.0 with 10 N NaOH, and adjust to 1 
litre final volume with water.  
 
100 mM EDTA  
153 
20ml   0.5 M EDTA 
80ml   dH2O 
 
5mg/ml ethidium bromide (EtBr) 
500mg  EtBr (Sigma H-3375)  
dH2O to 100ml 
 
Filter denaturing solution 
1.5M   NaCl 
0.5M   NaOH 
 
Filter neutralising solution 
1.5M   NaCl 
1mM   EDTA 
0.5M   Tris-HCL (pH=7.2) 
 
LB Medium  
10g   Bacto-Tryptone 
5g   Bacto-yeast extract 
10g   NaCl  
dH2O to 950ml, adjust pH  to 7.0 with 5M NaOH, and adjust volume to 1L with 
distilled water, aliquot into 250ml bottles and autoclave to sterilize.  
 
LB plates  
10g   Bacto-Tryptone 
10g   NaCl 
15g  Bacto-agar  
dH2O to 1 litre, autoclave to sterilize, cool to 55ºC, add antibiotic if desired, and pour 




1%  SDS 
Stored at room temperature 
 
PCR 10x reaction buffer 
100mM  Tris-HCL (pH 8.3)  
15mM  MgCl2 
500mM  KCL 
 
Phenol/chloroform/isoamyl alcohol (25:25:1)  
100ml   TE-saturated phenol 
100ml  chloroform 
4ml  isoamyl alcohol 
154 
 
Phosphate –Buffered Saline (PBS) 
8g   NaCl 
0.2g    KCL 
1.44g    Na2HPO4  
0.24g    KH2PO4  
dH2O to 800ml, adjust pH  to 7.4 with 1N HCL and adjust volume to 1L with distilled 
water.   
 
4% Paraformaldyhide (PFA) 
4g  PFA powder 
Make up to 100ml with PBS 
 
10% SDS (sodium dodecyl sulfate)  
10g   SDS (Fisher S529-3) 
dH2O to 100ml 
 
SOC Media 
2% w/v  Bacto- tryptone 
0.5% w/v  Bacto-yeast extract 
0.05%   NaCl 
Autoclave and add the following filter sterilised reagents. 1% (v/v) 1M MgCl2, 1% 
(v/v) 1M MgS04 and 0.1% (v/v) 2M glucose solution. 
 
3M NaOAc, pH 4.5  
408.24g         NaOAc-3H2O 
Dissolve in approx. 800ml dH2O, adjust pH to 4.5 with glacial acetic acid and bring to 
a final volume of 1 L with dH2O.  
 
10M NaOH (sodium hydroxide)  
40g   NaOH dissolved  
dH2O to 100ml 
 
Southern denaturing solution 
0.4M   NaOH 
0.6M   NaCL 
 
Southern neutralisation solution 
1.5M   NaCL 
0.5M   Tris-HCL (pH=7.5) 
 
SSC (20X) (standard saline-citrate) 
88.3g   sodium citrate  
175.3g  NaCl  
Dissolved in approximately 900ml water, adjust pH to 7.0 with 1N HCL and bring 
final volume to 1L.  
 
1X SSC  
5ml   20X SSC  
95ml   dH20 
155 
10 X TBE 
109g   Tris base 
55g   boric acid  
9.3g   EDTA  
dH2O to 1L 
 
TE  buffer  
10ml   1 M Tris-HCl (pH 7.6) 
2ml   0.5 M EDTA 
dH2O to 1L 
 
Tissue Lysis Buffer (TTLB) 
100mM  Tris HCL (pH 8.5) 
5mM   EDTA 
200mM  NaCl 
0.2%   SDS 
Proteinase K added to final concentration of 100µg /ml prior to use. 
 
Transfer Buffer 
1.45g   Tris buffer 
7.2g   Glycine 
200ml   methanol 
dH2O to 1L 
 
Tris-Buffered Saline (TBS) 
8g   NaCl 
0.2g   KCL 
3g   Tris base  
dH2O to 800ml, adjust pH to 7.4 with 1N HCL and bring final volume to 1L.  
 
TBS-Tx 
100ml   10x TBS 
1ml   0.1% Triton-X100 
dH2O to 1L 
 
1M Tris-HCl, pH 7.6, 8.0, 8.5, 9.0, 9.5  
121.1g  Tris base 
dH2O to 800ml 
Adjust pH with concentrated HCl and then add dH2O to 1 L. 
 
Type III loading buffer 
0.25%  bromophenol blue 
0.25%  xylene cyanol 
30%  glycerol 
 
2XTY medium 
16g   Bacto- tryptone 
10g  Bacto-yeast extract 
5g  NaCl 




8.2.1 Apc Immunohistochemistry 
A. Dewaxing:    
-Xylene   2 x 10 mins 
 -100% EtOH   2 x 5 mins 
 -95% EtOH   1 x 5 mins 
 -90% EtOH   1 x 5 mins 
 -70% EtOH   1 x 5 mins 
 -50% EtOH   1 x 5 mins 
 -PBS    1 x 5 mins 
 
B. Antigen Retrieval:   
-10mM Na Citrate (pH6)  4 x 5 mins at full power 
 -Cool slides    20 mins on ice 
 -PBS    1 x 5 mins 
 
C. Primary Antibody: 
 -Block slides in PBSTx (0.1% Tx), 10% NGS  15-30mins @ RT 
 -Apply 10 Ab (at 1:500 conc. in PSBTx/NGS) O/N @ 40C 
 
Next day: 
 -Wash in PBSTx   2 x 5 mins 
 -Apply Peroxidase block  1 x 5 mins 
 -Wash in PBSTx  2 x 5 mins 
 
D. Secondary Antibody 
 -Apply 150µl HRP 20 Ab 30 mins 
 [At this stage, make up DAB solution: 2ml substrate + 2 drops (40µl) DAB] 
 -Wash in PBSTx  3 x 5 mins 
 
E. Colour Development 
 -Apply >200µl DAB mix and incubate in dark 
 -Observe every 2 mins (colour normally develops within 3 – 10 mins) 
 
F. Counterstain (optional) 
 -(Fresh filtered) Haematoxylin  5 secs (for light stain) 
 - Water    1 min 
 -STWS    1 min 
 -Water     1 min 
 
G. Mounting 
 -70% EtOH    1 min 
 -90% EtOH    1 min 
 -100% EtOH    2 x 2 min 
 -Xylene    2 x 5 min 




APC antibody is from Santa Cruz. It’s a rabbit polyclonal and works on wax sections. 
It’s a C terminal Ab, so should should not bind in areas of APC floxed deletion.  
Order: Insight Biotechnology Limited. PO Box 520, Wembley, Middlesex, HA9 
7YN, UK. Tel: +44 20 8385 0303. Cat # sc-896. Rabbit anti-Human APC (C-20). 
NGS = Normal Goat Serum 
 
 
Envision Kit: Dako envision plus HRP rabbit kit. Cat # K4010.  
 
 
8.2.2 β-catenin Immunohistochemistry 
A. Dewaxing: 
 -2 x 7 mins in xylene 
 -5 mins in each alcohol (100% > 90% > 70%) 
 -Rinse in dH2O 
 
B. Antigen Retrieval: 
-Microwave 3 x 5 mins in 10mM Na-Citrate buffer (pH6) 
 -Leave for ~30 mins to cool 
 
-Wash in water 
 
-Apply 150µl peroxidase block (bottle 1)  
-Incubate 5 mins 
 -Rinse with water 
 -Place in TBS 
 
C. Primary Antibody: 
-Apply 350µl Antibody buffer (TBS/20% rabbit serum) 
 -Leave for ~10 mins to equilibriate 
-Apply 200µl 10 antibody (between 1/50 - 1/200 dilution in Ab buffer)  
 -Incubate for 45 mins at room temp 
 -Rinse with water 
 -Place in TBS 
 
-Make up DAB solution (needs to sit for ~10 mins) 
 -1.5 ml buffered substrate (bottle 3a) + 30µl DAB (bottle 3b) 
 -Mix solution 
 
D. Secondary Antibody 
-Apply 150µl HRP anti-mouse (bottle 2) per slide 
 -Leave for 30 mins 
 -Put slides back into TBS 
 -Change the TBS 
 
E. Colour Development 
-Apply 150µl pre-prepared DAB solution per slide 
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 -Do this quickly as the colour comes up very quickly 
 -Will probably only take a maximum of 10 mins 
 
-Rinse twice in water (pour contaminated water into DAB jug) 
 
F. Counterstain (optional) 
-Approx 10-20 sec haematoxylin and ~1 min eosin counterstain  
  
G. Mounting 
-Dehydrate through alcohol series for ~2 mins in each 
 -2 x 10 mins in xylene 
 -Mount with DPX 
 
 
Citrate buffer (10mM sodium citrate pH6.0) – Na3Citrate.2H2O: 294.1g/mole 
-10x (100mM): 29.4g/l + 2.9ml conc. HCl gives pH6.0 
-Dilute to 10mM (ie 100ml of 10xbuffer and 900ml ddH2O) 










-ddH2O to 800ml, adjust pH to 7.5 with conc. HCL and bring final volume to 1L. 
 




Antibody solution (Per slide) 
Conc.  µl Ab  µl Ab buffer 
1:50  4µl  196µl 
1:100  2µl  198µl 




8.2.3 Southern Blot Protocol 
 
A. Making Probe 
 
Set up restriction digest  
-40ul midi DNA 
-5ul buffer H 
-5ul EcoR1 
 
-Run 1ul DNA on a gel to make sure it has cut properly, then run the rest on a gel 
-Cut band out of gel and gel purify 
 
B. Making Southern Quality DNA 
 
-Tissue (eg half cerebellum) – 0.5ml TTLB + proteinase K (O/N @550C) 
-Equal vol Phenol Cholorform (eg 500µl) mix by inverting (10mins) 
-Take aqueous phase into clean tube 
-Add 1/10 vol 3M NaOAc pH 5.5 (50µl) and top up with 100% EtOH (800µl) 
-Shake hard 
-Can see DNA as white precipitate 
-Pick up with yellow tip 
-Dip into next epp containing 70% EtOH to wash 
-Transfer intoclean empty labelled epp 
-Leave open ~2-3h to allow EtOH to evaporate 
-Add ~200µl TE buffer (depends on how much DNA there is) 
-Resuspend by shaking (O/N @ 370C) 
 
C. Cutting DNA   
      If using SacI (HC) enzyme (80U/µl) 
40µl DNA      41µl DNA 
5µl 10x Buffer     5µl 10x Buffer 
2µl Spermidine     2µl Spermidine 
2µl Enzyme (≥50U)      1µl Enzyme (80U) 
 
O/N @ 370C 
 
-Then run ~2µl on 0.8% minigel to check it cut properly 
-If it cut properly, run 50µl on a maxi gel 
 
D. Maxi gel 
 
300ml of 0.8%  
 -300ml 1xTBE 
 -2.4g Saekem LE agarose 
 -*NO ETHIDIUM* 
-Leave to set for 1h 
- ~2.5L buffer to fill tank (add this in gel room) and leave for further 30mins 
-Add 10µl Loading Buffer to each 50µl sample and load gel 





-Remove gel from box and put in square container 
-Add some of the running buffer and to this add ~100µl ethidium 
-Shake for 20mins 
-While this is happening, make up HCl solution for the acid nic step 
 -500ml H20 + 12.5ml conc HCl 
-Cut off extra lanes and take a picture of gel (with fluorescent ruler next to ladder) 
-Remove gel from holder, and GENTLY place in square box 
-Pour over ~ 250ml HCl mix and shake for 30mins 
-Denat solution (2 x 30mins) 




-Fill the bottom of the transfer dish with 20xSSC 
-Place gel on the wick paper (wick paper is Whatman 3mm paper) 
-We want a water tight seal so need to use saran wrap and cut tightly around gel 
-Dampen the surface of the gel with 20xSSC  
-Cut hybond paper to the exact size of the gel (in cupboard with maxi tank) 
-Cut 4 pieces of Whatman (3mm) paper to the exact size of the gel 
-Identify the hybond paper using a sharpie pen 
-Dip the hybond paper into 2xSSC and put face (writing) side down on the gel 
 -Use Millipore tweezers to do this 
-Wet 2 pieces of whatman paper and put them on top 
-*important* Break a 10ml pipette and roll it across the paper to ensure all the 
air bubbles are out  
-Put 1 roll of Kleenex tissues on top and place a tray with a full 1L bottle for weight 
-Leave for ~2h and replace Whatman paper and Kleenex towels and leave O/N 
 
F. Fix DNA to hybond paper 
 
-Take off all the layers of paper 
-Put a little 2xSSC on saran wrap, then wrap hybond paper in that 
 -crosslinking works better if the membrane is wet 
-Cross link in machine (run on automatic program)  
-Remove excess water with Whatman paper and allow to air dry 
-Make a holder with Whatman paper, place hybond inside and tape the edges closed 
-Bake in oven @1200C for 15mins 




G. Radioactive part: 
 
-Fill out radioactivity forms 
-Heat 2 water baths (37 and 1000C) and monitor all surfaces and sign in 
-Denature DNA (want to label 25ng DNA per southern) and Salmon Sperm (SS) 
 -Make up 45µl (eg 44.5µl buffer TE, 0.5µl DNA proble, if probe conc is 50ng/µl) 
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-1000C for 5’ 
-straight onto ice for 1 min  
-spin DNA down briefly 
 
-Add the 45µl ontop of the labelling mix (don’t mix at this stage) 
-Then add 5µl 32P (pipette up and down ~12 times to mix) 
-370C for 10 mins (put lead top over tubes) 
-Add 5µl 0.2M EDTA (to stop the reaction) 
-Use Selfadex column (little porus beads in buffer) Protocol for this is on the fridge on left of centrifuge 
 -snap bottom off column, then put in screw tube and spin buffer 1 min 
 -Discard buffer and add the pink 32P mix to the centre of gel in new tube 
-spin for 2mins you should be left with the clear labelled probe in tube. This should register off the scale at 
about 6cm from the Geiger counter if the probe has labelled well. 
-Put in lead pot (or Perspex slide rack) then into freezer 
 
[monitor work area] 
 
H. Prehybridise the Filter 
-Wet membrane and filter and roll filter in membrane  
-Unroll this inside the hyb tube 
-Add 20ml buffer and 200µl SS (at 100µg/ml)  
 -seal lid and put in hyb oven (600C) for ~3h 
-Put SS back in freezer 
 
I. Hybridisation stage 
-After 3h, put SS and probe into 1000C H2O bath for 10mins (from frozen) 
 -then straight onto ice again so the DNA can not re-anneal  
-Pour away prehyb buffer and add 10ml Hyb buffer with 100µl SS and all the probe 
 -Put back in the oven O/N 
 
Next day 
-Pour radioactive probe down sink (make sure water is running) 
-Give 1 quick wash with wash buffer (Church wash) 
-Then 30’ washes @650C until you see a big fall in radiation levels 
 -when this happens, stop washes 
-Put filter face down on saran wrap and wrap it up 
 -Wash nylon mesh and bottle and lid to eliminate the radioactive waste 
-Estimate how much radiation went down the sink (approx 80%) and how 
much went into solid bin (approx 20%) 
-Need to fill out 3 sheets with this info 
-Put filter in cassette and place in -800C freezer O/N 
 
Next day 
-Turn processor on (takes 30mins to heat up), and take cassette out of freezer to warm up 




-Note the stock number (DB number) and mark this on pot of isotope 
-We use 5µl 32P per probe 
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-When you dispose of isotope, you have to record that 
-We estimate 80% goes down sink and 20% goes into solid waste  
 -There are 2 green books in hot room for this information 
 -There is also a sheet on solid waste bin for amounts of waste 
 
 
Southern Denaturing solution 
 
 Mol wt.  Per litre 5 litres 
0.5M NaOH 40 20g 100g 
1.5M NaCl 58.44 87.66g 438.3g 
 
Southern Neutralising solution 
 
 Mol wt.  Per litre 5 litres 
0.5M Tris pH 7.0 121.14 60.57g 302.85g 




 Mol wt.  Per litre 5 litres 
3M NaCl 58.44 175.32g 876.6g 
0.3M Na-citrate 294.10 88.23g 441.15g 
       
 
Church and Gilbert Hybridisation Solutions 
 
Church Hybridisation Mix 
250ml 0.5M NaPO4 pH 7.2    0.5M PO4  
175ml 20% SDS (or 350ml 10% SDS)  7% SDS 
1ml 0.5M EDTA     1mM EDTA 
5g BSA      1% BSA 
 
Top up to 500ml 




50ml 20% SDS (or 100ml 10% SDS)  1% SDS 
2ml 0.5M EDTA     1mM EDTA 
40ml 0.5M NaPO4 pH 7.2    40mM PO4 
 
Top up to 1 litre 
 
 
0.5M NaPO4 pH 7.2 
134g Na2HPO4.7H2O   or 71g anhydrous Na2HPO4 
4ml H3PO4     or 89g dihydrate 
 
Top up to 1 litre 
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Anhydrous Na2HPO4   Mwt = 141.96 
Heptahydrate  Mwt = 267.96 
Dihydrate  Mwt = 177.99 
 
 
Denatured Salmon Sperm DNA 
100mg Deoxyribonucleic acid sodium salt (S.S.) [ICN biomedicals Inc. Cat.#152275] 
10ml H2O 
 
-Pass vigorously through a 17-G needle 20 times to shear DNA (unless presheared) 
-Place in boiling water bath for 10mins then straight onto ice 




Amersham Biosciences (http://www4.amershambiosciences.com) 
-Probe Quant G50 Micro Columns (Catalogue #27-5335-01 cost £130 in Jan 06) 






8.2.4 Virus Preparation for the TVA System  
 
Select a vector, either RCASBP(A) or other ALV-A vector  
 
Clone your gene of interest into the selected vector   
 
Purify the plasmid DNA using a method that will yield pure DNA (Cesium chloride 
gradients, Qiagen Maxiprep, etc.)   
 
Prepare either chicken embryo fibroblast cells or DF1 chicken fibroblasts for 
transfection.  The protocol below is for DF 1 cells.  
 
Maintain DF1 cells in growth medium (DMEM with high glucose, 10% fetal bovine 
serum, 2 mM L-glutamine, 10 units/ ml penicillin, 10 ug/ml streptomycin) at 37oC 
and 5% CO2.  
 
 
Transfection Protocol using GeneJuice (for 35mm dish) 
DAY 1 
-Seed cells at appropriate density (50-80%) – depends of cell type and protocol etc 
 -Seed into Penicillin/Streptomycin (pen/strep) free media 
 
DAY 2 
-Change medium=> -aspirate 
   -wash once in PBS 
-cover cells in 3ml media (pen/strep free DMEM can work with 
or without serum)  
 
Transfection Mix 
*For most cell lines the optimal ratio of genejuice to DNA is 3µl genejuice to 1µl 
DNA, but the ratio can be varied from 2-6µl per µg DNA during optimisation 
 
-100µl serum free DMEM + 3µl genejuice 
-mix thoroughly 
-Incubate at RT for 5 mins 
-For each 35mm dish to be transfected, add 1µg to the GJ/serum-free mix. Gently 
pipette up and down 
-Incubate the mixture at RT for 5-15mins 
-Add the mixture dropwise (evenly over the plate) to the cells in complete growth 
medium. Gently rock the dish, as swirling concentrates the transfection mix in the 
centre of the plate. 
-Remove the transfection mix after 2-8 hrs incubation and replace with complete 
growth medium – this is an optional step 
-Incubate the cells for 24-72 hrs at 370C (5% CO2) 
165 





To obtain high titer viruses for stocks, collect virus from cultures grown in minimum 
amounts of medium (5 ml/100 mm tissue culture dish) and approximately 24 hours 
after cells become confluent.  Harvests can be done every 12 hours, adding 5 ml of 
medium each time.  Typically, plates can be passed from 1 to 2 plates, resuming virus 
collection 18-24 hours after passage.  
 
Remove cell debris by low-speed centrifugation and store supernatant aliquots at –
80oC.  There is a typical loss of up to one log of viral titer after one cycle of freezing 
and thawing.  
 
ALV-derived viruses mutate frequently and mutant viruses that have lost the gene of 
interest commonly show a growth advantage.  Following multiple rounds of 
infections, culture supernatants may have many mutant viruses but due to viral 
interference, only a limited number of new infections occur in producer cells.  Viral 
mutations can be minimized by passing/propagating the producer cells.  New 
producer cells can be generated by infecting DF1 cells with stocks from frozen culture 




Expand virus-producer cells into 5-10 15-cm dishes depending up the amount of virus 
needed. 
 
When they are confluent, switch to DMEM/1% FBS, 20 ml/dish; grow overnight. 
 
Collect supernatant.  Remove cell debris by a low speed spin (3000 rpm,10 minutes, 
40C). 
 
Spin in a ultracentrifuge for 1.5 hr. at 26K (50,000 g), 4oC.  
 
Discard all but 1/100 of the supernatant.  Resuspend the pellet by vortexing for 2 min 
at a medium speed. 
 
 
Preparing RCAS containing DF-1 cells for injection into mice 
 
On day of experiment, RCAS containing DF-1 cells where trypsinised from T75 flask 
and a cell count was carried out to determine the number of cells in the flask. The 
cells were then resuspended in an appropriate volume of DMEM (lacking antibiotics) 
so that 1µl contained 1x104 RCAS containing DF-1 cells. This virus preparation was 
then aliquoted into eppendorfs. 
 
  
 
